NAME	MinION	PromethION	MGI	pwCF_ID	Sample date	IP vs OP	Hospital	Room	Age	Age groups	Paediatric vs Adult	Gender	Sample_Type	H2_Uncorrected	CH4_Uncorrected	CO2	H2_Corrected	CH4_Corrected	CH4/H2 ratio_corrected	Corr.	Culture Result (Matched with sequenced sample)	NTM	Pseudomonas Culture	Cutured in previous 12 months	Others cultured	IgE	Spec IgE	Spec IgG	Precipitins	FVC	FEV1	Best FEV1	FEV1/best FEV1	FEV1_RATIO_SCORE	FEV1_Obstruction_Rank	Cystic Fibrosis related diabetes (CFRD)	Pancreatic insufficiency (PI)	CF gene 1	CF gene 2	Notes	CFLD	CS_mucoid	CS_non-mucoid	CS_Pseudomonas aeruginosa	CS_Oral flora	CS_Stenophotomonas maltophilia	CS_Aspergillus fumigatus	CS_Aspergillus flavus	CS_Candida albicans	CS_Mycobacteroides abscessus	CS_Mycobacterium intracellulare	CS_Staphylococcus  aureus	CS_Inquilinus limosus	CS_Achromobacter xylosoxidans	CS_Burkholderia cepacia	CS_NTM_(Smear negative)	CS_Mycolicibacter terrae	CS_Aspergillus nidulans	CS_MAC_(Smear negative)	CS_NTM_Smear_Status	CS_Penicillium	CS_Aspergillus niger	CS_Aspergillus terreus	CS_Scedosporium apiospermum	CS_Lomentospora prolificans	CS_Acremonium species	CS_MDR_Pseudomonas aeruginosa	CS_Haemophilus influenzae	CS_Scedosporium apiospermum.1	P12M_0_Nothing	P12M_1_Staphylococcus aureus	P12M_2_Pseudomonas aeruginosa	P12M_3_Stenotrophomonas maltophilia	P12M_4_Rapid NTM	P12M_5_Slow NTM	P12M_6_Aspergillus	P12M_7_Burkholderia cepacia	P12M_8_Haemophilus influenza	P12M_9_Streptococcus pneumoniae	P12M_10_Achromobacter xylosoxidans	P12M_11_Serratia marcesens	P12M_12_Inquilinus limosus	P12M_13_Scedosporum apiospermum	P12M_14_Moraxella catarrhalis	Next PA Positive Date	Positive for PA within next 12 months	Culture for next sample	N12M_Pseudomonas aeruginosa	N12M_Pseudomonas aeruginosa (multi-resistant)	N12M_mucoid	N12M_non_mucoid	N12M_MAC	N12M_M intracellulare	N12M_Candida albicans	N12M_Achromobacter xylosoxidans	N12M_Aspergillus fumigatus	N12M_Stenotrophomonas maltophilia	N12M_Staphylococcus aureus	N12M_M gordonae	N12M_M chelonae	O_Penicillium species	O_Enterobacter cloacae	O_Aspergillus Flavus	O_Mycobacterium abscessus	O_Cupriavidus gilardii	O_Mycobacterium intracellular	O_Scedosporium apiospermum	O_Pseudomonas aeruginosa (multi-resistant)	O_Streptococcus pyogenes	O_Pseudomonas aeruginosa (non-mucoid)	O_Chryseobacterium indologenes	O_Bordetella species	O_Klebsiella oxytoca	O_Mycobacterium mucogenicum	O_Mycobacterium scotochromogen	O_Acinetobacter species	O_Enterobacter species	O_Aspergillus niger	O_Aspergillus terreus	O_Pseudomonas aeruginosa (mucoid)	O_Proteus mirabilis	O_talaromyces purpurogenus	O_Trichosporon mycotoxinivorans	Antibiotics (duration)	Antibiotics_YN	IV	INH	PO	2 Amphotericin B (Ambisome)_INH	4 Amikacin_IV	2 Amikacin_INH	2 Amoxicillin & Potassium clavulanate (Aug Duo)_PO	3 Azithromycin_IV	2 Azithromycin_PO	3 Aztreonam_IV	3 Cefopime_IV	4 Cefoxitin_IV	3 Ceftazidime_IV	2 Ceftazidime_INH	1 Cephalexin_PO	2 Ciprofloxacin_PO	2 Clarithromycin_PO	2 Clofazimine PO	4 Colistin_IV	2 Colistin_IHN	1 Flucloaxcillin_PO	3 Imipenem	1 Itraconazole (Lozenoc)_PO	3 Ivacaftor (Kalydeco)	3 Meropenem_IV	3 Methylpredinosolone_IV	3 Omalizumab_SC	3 piperacillin sodium, tazobactam sodium (Tazocin)_IV	2 prednisolone_PO	1 Sulfamethoxazole_trimethoprim (Bactrim)_PO	3 tobramycin_IV	2 tobramycin_INH	Sum of antibiotics	Sum of meds	Sum of antifungals	Sum of steroid + mabs	DNA_extraction_ conc	SAGC ULN	DNA Conc. (ng/ul)	Index I7	Index I5	Mean_Size_BP	Total Clusters Passing Filter (Million)
623361_20180123_S	623361_20180123_S		623361_20180123_S	623361	127	OP	RAH	Chest Clinic 9	18	4	Adult	M	S	6.0	2.0	4.1	8.0	3.0	0.375	1.34	P. aeruginosa (mucoid), S. maltophilia, A. fumigatus, oral flora	0.0	1.0	2; 6; 10						92.0	84.0	89	0.943820225	2.0	1.0	No	Yes	F508	F508		No	1	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	2018-01-23	Yes	Mucoid P. aeruginosa - resistant to amikacin, gentamicin, ciprofloxacin, S - tobramycin, piperacillin/tazobactam, ceftazidime, meropenem; Tested positive for S. maltophilia, A. fumigatus over the next 12 months	1.0	1.0	1.0											0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No antibiotics for >2/12	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.778	SAGCFN_22_01764	33.6	GAGATTCC	GGCTCTGA	468	2.4
634207_20180510_S			634207_20180510_S	634207	234	IP	WCH	Adol Rm9	17	3	Paediatric	F	S	39.0	15.0	4.2	50.0	19.0	0.38	1.27	Oral flora; Aspergillus flavus	0.0	0.0	1; 6; 11	Penicillium; Enterobacter cloacae	1750.0	31.0	122.0	1.0	87.0	79.0	94	0.840425532	3.0	1.0	Impaired	No	F508	A455	2 week admission for acute on chronic bronchitis	No	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0		No		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tobramycin/? For 1/7)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0.0	SAGCFN_22_01856	7.82	CGGACGATTC	CCACCACCTA	651	2.9
634207_20180517_S			634207_20180517_S	634207	241	IP	WCH	Adol Rm9	17	3	Paediatric	F	S	26.0	10.0	4.0	36.0	14.0	0.388888889	1.37	Oral flora; Aspergillus flavus	0.0	0.0	1; 6; 11	Penicillium; Enterobacter cloacae					84.0	79.0	94	0.840425532	3.0	1.0	Impaired	No	F508	A455	2 week admission for acute on chronic bronchitis	No	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0		No		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tobramycin/? For 8/7)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0.134	SAGCFN_22_01827	22.8	AGCGATAG	CCTATCCT	633	2.4
639354_20171206_S	639354_20171206_S	639354_20171206_S	639354_20171206_S	639354	79	IP	WCH	Adolescent 10	17	3	Paediatric	F	S	10.0	2.0	3.6	15.0	3.0	0.2	1.52	P. aeruginosa (mucoid)	0.0	1.0	2		107.0	4.7		2.0	85.0	53.0	77	0.688311688	3.0	2.0	No	No	F508	p.Arg851	2 week admission for 25% decline in PFT	No	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2017-12-06	Yes	P. aeruginosa intermediate to meropenem, sensitive to everything else; Tested positive for MDR P. aeruginosa, MSSA over next 12 months	1.0	1.0									1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	IV tob (x1 dose)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	3.54	SAGCFN_22_01742	20.8	ATTACTCG	TAATCTTA	337	4.9
650003_20180207_S	650003_20180207_S		650003_20180207_S	650003	142	IP	WCH	Adol Room 1	17	3	Paediatric	M	S	31.0	5.0	4.2	40.0	7.0	0.175	1.3	P. aeruginosa (non-mucoid); A. fumigatus	0.0	1.0	1; 2; 4; 6		11.0	0.0		1.0	83.0	86.0	87	0.988505747	1.0	1.0	Yes	Yes	F508	F508	2/52 admission. NB: Pseudomonas nitroreducens positive in next 12 months; Was +ve for PA 6 days before this sample (7/2/18); was positive in the past 12 months; Tested positive for Aspergillus fumigatus/C. albicans/M. abscessus/Pseudomonas nitroreducens/S. aureus)	Yes	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-02-07	Yes	P. aeruginosa - fully sensitive; Tested positive for Aspergillus fumigatus/C. albicans/M. abscessus/Pseudomonas nitroreducens/S. aureus over the next 12 months	1.0				1.0		1.0		1.0		1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (Long-term PO azithromycin, PO clofazamine; ceased long-term inhaled amikacin 1/7 ago; started IV tobramycin and IV ceftazadime 1/7 ago)	Yes	1	1	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	5	0	0	0.552	SAGCFN_22_01778	8.28	GAATTCGT	ATAGAGGC	476	5.7
650003_20180213_S			650003_20180213_S	650003	148	IP	WCH	Level 6 Treatment	17	3	Paediatric	M	S	3.0	1.0	4.0	4.0	1.0	0.25	1.48	A. fumigatus	0.0	0.0	1; 2; 4; 6						87.0	89.0	89	1.0	1.0	1.0	Yes	Yes	F508	F508	2/52 admission. NB: Pseudomonas nitroreducens positive in next 12 months; Was +ve for PA 6 days before this sample (7/2/18); was positive in the past 12 months; Tested positive for Aspergillus fumigatus/C. albicans/M. abscessus/Pseudomonas nitroreducens/S. aureus)	Yes	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-02-07	Yes	P. aeruginosa - fully sensitive; Tested positive for Aspergillus fumigatus/C. albicans/M. abscessus/Pseudomonas nitroreducens/S. aureus over the next 12 months	1.0				1.0		1.0		1.0		1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (Long-term PO azithromycin, PO clofazamine; ceased long-term inhaled amikacin 7/7 ago; started IV tobramycin and IV ceftazadime 7/7 ago)	Yes	1	0	1	0	0	1	0	0	1	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	5	0	0	0.289	SAGCFN_22_01800	27.6	TAATGCGC	GTACTGAC	572	3.5
658355_20171204_S	658355_20171204_S		658355_20171204_S	658355	77	OP	WCH	Gilbert S Meeting	16	3	Paediatric	M	S	14.0	2.0	3.8	20.0	3.0	0.15	1.44	Oral Flora	0.0	0.0	2; 3; 6; 10		175.0	1.9		1.0	90.0	87.0	96	0.90625	2.0	1.0	Impaired	Yes	F508	F508		No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	2018-02-26	Yes	PA resistant to amikacin, cefipime, ciprofloxacin, gentamicin, S - ceftazidime, meropenem, piperacillin/tazobactam, tobramycin. Tested positive for C. albicans, MDR P. aeruginosa, M. abscessus (massiliense) over next 12 months	1.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (3/52 prior inhaled tob)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.433	SAGCFN_22_01789	16.6	CTGAAGCT	AGGCGAAG	507	4.5
658355_20180122_S	658355_20180122_S		658355_20180122_S	658355	126	OP	WCH	Level 6 DK Office	16	3	Paediatric	M	S	13.0	2.0	3.3	22.0	3.0	0.136363636	1.17	Candida albicans	0.0	0.0	2; 3; 6; 10						90.0	86.0	96	0.895833333	3.0	1.0	Impaired	Yes	F508	F508		No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	2018-02-26	Yes	PA resistant to amikacin, cefipime, ciprofloxacin, gentamicin, S - ceftazidime, meropenem, piperacillin/tazobactam, tobramycin. Tested positive for C. albicans, MDR P. aeruginosa, M. abscessus (massiliense) over next 12 months	1.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No antibiotics for >2/12	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.761	SAGCFN_22_01767	26.4	GAGATTCC	CAGGACGT	573	2.2
658355_20180321_S	658355_20180321_S		658355_20180321_S	658355	184	IP	WCH	Adol 3	16	3	Paediatric	M	S	31.0	5.0	4.2	40.0	7.0	0.175	1.3	P. aeruginosa (multi-resistant); A. fumigatus	0.0	1.0	2; 3; 6; 10		197.0	2.3		1.0	86.0	82.0	96	0.854166667	3.0	1.0	Impaired	Yes	F508	F508	2 week PA eradication	No	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	2018-10-12	Yes	PA resistant to amikacin, cefipime, ceftazidime, piperacillin/tazobactam, ciprofloxacin, gentamicin, S - meropenem, tobramycin	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (2 doses of IV ceftazidime, 2/52 of Inh tob and PO cipro prior)	Yes	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	3	0	0	1.44	SAGCFN_22_01751	33.4	TCCGGAGA	CAGGACGT	487	3.4
658355_20180327_S			658355_20180327_S	658355	190	OP	WCH	Level 6 Treatment	16	3	Paediatric	M	S	4.0	2.0	4.0	5.0	3.0	0.6	1.37	A. fumigatus	0.0	0.0							87.0	88.0	96	0.916666667	2.0	1.0	Impaired	Yes	F508	F508	2 week PA eradication	No	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0																2018-10-12	Yes	PA resistant to amikacin, cefipime, ceftazidime, piperacillin/tazobactam, ciprofloxacin, gentamicin, S - meropenem, tobramycin	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1/52 of IV ceftazidime/tobramycin, preceded by 2/52 of inh tob and po cipro)	Yes	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	4	0	0	0.155	SAGCFN_22_01823	14.4	TCTCGCGC	CAGGACGT	691	2.8
658355_20170925_S			658355_20170925_S	658355	7	OP	WCH	Level 6 DK	16	3	Paediatric	M	S	11.0	2.0	3.6	17.0	3.0	0.176470588	1.52	Oral Flora	0.0	0.0	2; 3; 6; 10						89.0	86.0	98	0.87755102	3.0	1.0	Impaired	Yes	F508	F508		No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	2018-02-26	Yes	PA resistant to amikacin, cefipime, ciprofloxacin, gentamicin, S - ceftazidime, meropenem, piperacillin/tazobactam, tobramycin. Tested positive for C. albicans, MDR P. aeruginosa, M. abscessus (massiliense) over next 12 months	1.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (6/52 PO cipro + Inh tob, 2/52 IV tob/ceftaz prior)	Yes	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	4	0	0	0.0	SAGCFN_22_01861	0.558	AGGATGTCCA	AACGTCCAGT	676	0.3
673895_20180205_S	673895_20180205_S		673895_20180205_S	673895	140	IP	WCH	Adol Room 11	16	3	Paediatric	M	S	6.0	1.0	3.2	10.0	2.0	0.2	1.71	Candida albicans	0.0	0.0	1; 3; 6; 12	Previous A. flavus; previous Inquilinus limosus					75.0	66.0	81	0.814814815	3.0	1.0	No	Yes	F508	F508	3/52 admission for low lung function and slow response	Yes	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2020-02-10	No (over 12 months)	Tested positive for Inquilinus limosus, Serratia marcescens, C. albicans, Candida dubliniensis, S. aureus over next 12 months	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV meropenem and IV tobramycin for 2/52, ongoing PO itraconazole, preceded by oral augmentin)	Yes	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	1	0	3	4	1	0	1.05	SAGCFN_22_01756	19.4	CGCTCATT	GGCTCTGA	524	5.8
673895_20180122_S	673895_20180122_S		673895_20180122_S	673895	126	OP	WCH	Level 6 Treatment	16	3	Paediatric	M	S	13.0	2.0	3.0	24.0	4.0	0.166666667	1.83	Inquilinus limosus	0.0	0.0	1; 3; 6; 12	Previous A. flavus	374.0	0.4		0.0	70.0	64.0	81	0.790123457	3.0	2.0	No	Yes	F508	F508	3/52 admission for low lung function and slow response	Yes	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2020-02-10	No (over 12 months)	Tested positive for Inquilinus limosus, Serratia marcescens, C. albicans, Candida dubliniensis, S. aureus over next 12 months	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2/12 of augmentin duo and itraconazole longterm	Yes	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	2	1	0	0.638	SAGCFN_22_01775	17.2	ATTCAGAA	CAGGACGT	552	4.8
676138_20171001_S			676138_20171001_S	676138	13	IP	WCH	Adolescent 8	15	3	Paediatric	F	S	0.0	0.0	3.2	0.0	0.0		1.71	A. xylosoxidans; Burkholderia cepacia	0.0	0.0	3; 5; 6; 7; 10; 11						74.0	54.0	56	0.964285714	1.0	1.0	Yes	Yes	F508	F508	2 week admission - BCC eradication	Yes	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	2017-12-12	Yes	A. xylosoxidans; P. aeruginosa; A. fumigatus. MDR P. aeruginosa -  sensitive to piperacillin/tazobactam only, resistant to everything else	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1 dose of meropenem and ceftazidime)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	2	0	0	0.0	SAGCFN_22_01863	5.7	CTTACGAACT	CTCAGTCCGT	333	2.5
676138_20171009_S			676138_20171009_S	676138	21	IP	WCH	Adolescent 8	15	3	Paediatric	F	S	0.0	0.0	3.7	0.0	0.0		1.48	A. xylosoxidans; A. fumigatus	0.0	0.0	3; 5; 6; 7; 10; 11						77.0	54.0	56	0.964285714	1.0	1.0	Yes	Yes	F508	F508	2 week admission - BCC eradication	Yes	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	2017-12-12	Yes	A. xylosoxidans; P. aeruginosa; A. fumigatus. MDR P. aeruginosa -  sensitive to piperacillin/tazobactam only, resistant to everything else	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (9/7 of IV meropenem and ceftazidime)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	2	2	0	0	0.084	SAGCFN_22_01839	12.3	AGATTAGCGT	ATATAAGGCG	512	2.8
676138_20180405_S			676138_20180405_S	676138	199	OP	WCH	Level 6 Treatment	15	3	Paediatric	F	S	8.0	3.0	3.7	12.0	4.0	0.333333333	1.48	?no sample			3; 5; 6; 7; 10; 11						74.0	50.0	56	0.892857143	3.0	1.0	Yes	Yes	F508	F508	2 week admission for acute on chronic bronchitis	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	2018-03-23	Yes	A. xylosoxidans; P. aeruginosa; A. fumigatus	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tazocin/tobramycin for 2/52 and longterm s/c omalizumban, inhaled ambisome and PO itraconazole)	Yes	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	1	0	3	5	2	1	0.251	SAGCFN_22_01805	15.3	CGGCTATG	AGGCGAAG	582	4.2
676138_20180130_S	676138_20180130_S		676138_20180130_S	676138	134	OP	WCH	Level 6 AT Office	15	3	Paediatric	F	S	33.0	5.0	2.5	73.0	11.0	0.150684932	2.2	Candida albicans	0.0	0.0	3; 5; 6; 7; 10; 11						77.0	52.0	56	0.928571429	2.0	1.0	Yes	Yes	F508	F508	Next CF exacerbation 2 months	Yes	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	2018-03-23	Yes	A. xylosoxidans; P. aeruginosa; A. fumigatus	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (S/C omalizumab, Inh Ambisome, PO Lozenoc, PO bactrim - all >6months, except for bactrim 4 months)	Yes	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	1	0	0	2	4	2	1	0.33	SAGCFN_22_01796	19.4	TAATGCGC	GGCTCTGA	640	3.1
676138_20180323_S			676138_20180323_S	676138	186	IP	WCH	Adol 3	15	3	Paediatric	F	S	8.0	2.0	3.4	13.0	3.0	0.230769231	1.61	A. xylosoxidans; P. aeruginosa; A. fumigatus	0.0	1.0	3; 5; 6; 7; 10; 11		992.0	36.0		2.0	72.0	48.0	56	0.857142857	3.0	1.0	Yes	Yes	F508	F508	2 week admission for acute on chronic bronchitis	Yes	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	2018-03-23	Yes	A. xylosoxidans; P. aeruginosa; A. fumigatus	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (2 doses of IV tazocin, 1 dose IV tobramycin [running], long-term inhaled ambisome and oral bactrim)	Yes	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	4	4	1	0	0.224	SAGCFN_22_01813	39.0	TCCGCGAA	AGGCGAAG	371	1.6
701099_20180504_S			701099_20180504_S	701099	228	IP	WCH	Adol Rm6	15	3	Paediatric	F	S	25.0	9.0	4.8	29.0	10.0	0.344827586	1.14	S. aureus	0.0	0.0	1; 2		221.0	3.83	41.0	0.0	100.0	92.0	103	0.893203883	3.0	1.0	No	Yes	F508	F508	2/52 admission for acute on chronic bronchitis	No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for MSSA, A. fumigatus over the next 12 months									1.0		1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1/7 of IV ceftazidime, no IV tobramycin yet)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.05	SAGCFN_22_01849	11.2	TTACGCGCAT	TGTCGTTAAG	647	2.9
701099_20180517_S			701099_20180517_S	701099	241	OP	WCH	Level 6 Treatment	15	3	Paediatric	F	S	18.0	7.0	4.2	23.0	9.0	0.391304348	1.3	Oral flora	0.0	0.0	1; 2						102.0	98.0	103	0.951456311	1.0	1.0	No	Yes	F508	F508	2 week admission for acute on chronic bronchitis	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for MSSA, A. fumigatus over the next 12 months									1.0		1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV ceftazidime, IV tobramycin 2/52)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	0	0	0.0631	SAGCFN_22_01844	7.7	TTCCTCACGT	TGGCTCATGT	843	2.0
715927_20180205_S	715927_20180205_S		715927_20180205_S	715927	140	OP	WCH	Level 6 DK Office	13	3	Paediatric	F	S	38.0	6.0	3.4	61.0	10.0	0.163934426	1.61	Oral flora	0.0	0.0	1; 6		73.0	2.4		0.0	90.0	84.0	98	0.857142857	3.0	1.0	No	Yes	F508	F508	2/52 admission	Yes	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-03-18	No	Over 12 months later, P. aeruginosa x 2 (MDR - R to amikacin, gentamicin, tobramycin); Tested positive for P. aeruginosa ~ 13 months after the initial sample; tested positive for A. fumigatus over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (augmentin duo for 3/12)	Yes	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.326	SAGCFN_22_01797	16.5	TAATGCGC	AGGCGAAG	516	3.4
715927_20180213_S			715927_20180213_S	715927	148	IP	WCH	Adol Room 11	13	3	Paediatric	F	S	42.0	7.0	3.7	62.0	10.0	0.161290323	1.48	P. aeruginosa (non-mucoid); A. fumigatus	0.0	1.0	1;6		102.0	3.7		0.0	98.0	98.0	98	1.0	1.0	1.0	No	Yes	F508	F508	2/52 admission	Yes	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-03-18	No	Over 12 months later, P. aeruginosa x 2 (MDR - R to amikacin, gentamicin, tobramycin); Tested positive for P. aeruginosa ~ 13 months after the initial sample; tested positive for A. fumigatus over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (augmentin duo for 3/12, ceased 1/7 ago; 1/7 of IV tobramycin and IV tazocin)	Yes	1	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	3	3	0	0	0.234	SAGCFN_22_01811	31.0	TCCGCGAA	CCTATCCT	443	2.7
715927_20180226_S			715927_20180226_S	715927	161	OP	WCH	OPD 8	13	3	Paediatric	F	S	13.0	3.0	3.6	20.0	5.0	0.25	1.52	Oral Flora	0.0	0.0	1; 6						103.0	102.0	98	1.04	1.0	1.0	No	Yes	F508	F508	2/52 admission; New best for FEV1 (and FVC)	Yes	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-03-18	No	Over 12 months later, P. aeruginosa x 2 (MDR - R to amikacin, gentamicin, tobramycin); Tested positive for P. aeruginosa ~ 13 months after the initial sample; tested positive for A. fumigatus over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (2/52 IV tob/tazocin, preceding aug duo)	Yes	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.108	SAGCFN_22_01833	15.1	TAACTTGGTC	GATTCACGAC	510	2.6
748160_20180321_S	748160_20180321_S		748160_20180321_S	748160	184	IP	WCH	Adol 9	12	3	Paediatric	M	S	46.0	7.0	3.6	70.0	11.0	0.157142857	1.52	P. aeruginosa (non-mucoid; multiresistant)	0.0	1.0	2	Previous P. aeruginosa (non-mucoid; multi-resistant)	10.0	0.0		0.0	72.0	65.0	100	0.65	3.0	2.0	No	Yes	F508	F508	35% below best - 3 week admission and readmission within 2 months	Yes	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-05-21	Yes	P. aeruginosa (MDR - R to amikacin, gentamicin, tobramycin, cefepime, ciprofloxacin, piperacillin/tazobactam). was previously +ve on the 21/3/18; had previously cultured +ve for PA in past 12 months; Tested positive for C. albicans, MSSA over next 12 months	1.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (6 weeks of oral/inhaled ßantibiotics ¹ inhaled tobramycin, oral ciprofloxacin/azithromycin)	Yes	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.548	SAGCFN_22_01779	25.4	GAATTCGT	CCTATCCT	531	3.6
748160_20180329_S	748160_20180329_S		748160_20180329_S	748160	192	IP	WCH	Adol 9	12	3	Paediatric	M	S	1.0	1.0	3.4	2.0	2.0	1.0	1.61	Candida albicans (on sputum, not BAL)	0.0	0.0	2	Previous P. aeruginosa (non-mucoid; multi-resistant)					73.0	67.0	100	0.67	3.0	2.0	No	Yes	F508	F508	35% below best - 3 week admission and readmission within 2 months	Yes	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-05-21	Yes	P. aeruginosa (MDR - R to amikacin, gentamicin, tobramycin, cefepime, ciprofloxacin, piperacillin/tazobactam). was previously +ve on the 21/3/18; had previously cultured +ve for PA in past 12 months; Tested positive for C. albicans, MSSA over next 12 months	1.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tobramycin/tazocin for 8/7)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.483	SAGCFN_22_01785	18.2	CTGAAGCT	TATAGCCT	557	4.0
748699_20180410_S	748699_20180410_S		748699_20180410_S	748699	204	IP	WCH	Adolescent 1	12	3	Paediatric	M	S	9.0	2.0	3.7	13.0	3.0	0.230769231	1.48	Candida albicans	0.0	0.0	1; 2		9.0	0.0	58.0	0.0	90.0	98.0	111	0.882882883	3.0	1.0	No	Yes	F508	G542X	2 week admission for acute on chronic bronchitis	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-01	Yes	S. aureus; P. aeruginosa (mucoid, multiresistant); A. fumigatus; C. albicans	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tazocin and IV tobramycin For 12/7)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.586	SAGCFN_22_01777	14.8	GAATTCGT	TATAGCCT	519	4.6
748699_20190101_S			748699_20190101_S	748699	470	IP	WCH	MSSW 17	13	3	Paediatric	M	S								S. aureus; P. aeruginosa (mucoid, multiresistant); A. fumigatus; C. albicans	0.0	1.0	1; 2	Previous S. pyogenes	6.0	0.0	63.0	2.0	94.0	97.0	107	0.906542056	2.0	1.0	Impaired	Yes	F508	G542X	2/52 admission for acute on chronic bronchitis	No	1	0	1	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-01	Yes	S. aureus; P. aeruginosa (mucoid, multiresistant); A. fumigatus; C. albicans	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0			0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV ceftazidime x 2 doses, about to commence IV colistin)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.286	SAGCFN_22_01801	42.0	CGGCTATG	TATAGCCT	392	2.2
748699_20190109_S			748699_20190109_S	748699	478	IP	WCH	MSSW 17	13	3	Paediatric	M	S								Candida albicans; A. fumigatus; P. aeruginosa (mucoid, multiresistant)	0.0	1.0	1; 2	Previous S. pyogenes					94.0	97.0	107	0.906542056	2.0	1.0	Impaired	Yes	F508	G542X	2/52 admission for acute on chronic bronchitis	No	1	0	1	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-01	Yes	S. aureus; P. aeruginosa (mucoid, multiresistant); A. fumigatus; C. albicans	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0			0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV ceftazidime/colistin x 1/52)	Yes	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	1	0	0.214	SAGCFN_22_01815	43.6	TCCGCGAA	CAGGACGT	395	2.0
748699_20190114_S			748699_20190114_S	748699	483	IP	WCH	MSSW 17	13	3	Paediatric	M	S								Oral flora; C. albicans; P. aeruginosa (non-mucoid)	0.0	1.0	1; 2	Previous S. pyogenes	8.0	0.0	69.0	2.0	97.0	101.0	107	0.943925234	2.0	1.0	Impaired	Yes	F508	G542X	2/52 admission for acute on chronic bronchitis	No	0	1	1	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-01	Yes	S. aureus; P. aeruginosa (mucoid, multiresistant); A. fumigatus; C. albicans	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0			0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV ceftazidime/colistin x 2/52)	Yes	1	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	1	0	0.15	SAGCFN_22_01824	42.0	TCTCGCGC	GTACTGAC	352	2.0
748699_20180329_S	748699_20180329_S		748699_20180329_S	748699	192	IP	WCH	Adol 1	12	3	Paediatric	M	S	29.0	7.0	4.6	35.0	8.0	0.228571429	1.19	S. aureus	0.0	0.0	1; 2	Previous P. aeruginosa (non-mucoid; multi-resistant)				0.0	97.0	105.0	111	0.945945946	2.0	1.0	No	Yes	F508	G542X	2 week admission for acute on chronic bronchitis	No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-01	Yes	S. aureus; P. aeruginosa (mucoid, multiresistant); A. fumigatus; C. albicans	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0			0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	No (about to commence IV antibiotics - tobramycin and tazocin, first admission in 4 years)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.02	SAGCFN_22_01757	19.6	CGCTCATT	AGGCGAAG	472	6.0
752797_20180306_S			752797_20180306_S	752797	169	IP	WCH	Adolescent 3	12	3	Paediatric	M	S	8.0	2.0	4.1	11.0	3.0	0.272727273	1.34	S. aureus	0.0	0.0	1; 6						82.0	81.0	85	0.952941176	1.0	1.0	Impaired	Yes	F508	F508	2 week admission	Yes	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, MSSA over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1 dose of tazocin); 5 weeks of oral flucloxacillin	Yes	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	2	2	0	0	0.199	SAGCFN_22_01818	27.8	TCTCGCGC	ATAGAGGC	609	2.6
752797_20170918_S			752797_20170918_S	752797	0	OP	WCH	Level 6 Treatment	12	3	Paediatric	M	S	30.0	5.0	4.5	37.0	6.0	0.162162162	1.22	S. aureus	0.0	0.0	1; 2; 6		263.0	5.7		2.0	73.0	70.0	85	0.823529412	3.0	1.0	Impaired	Yes	F508	F508		Yes	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, MSSA over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (PO augmentin since discharge, 3/52 since IV methylprednisolone x 1st course, >2/12 since IV ceftaz and tob)	Yes	0	0	1	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	3	4	0	1	0.0	SAGCFN_22_01859	4.86	CGCGGTATCT	GATCGGTAAT	323	2.5
752797_20170927_S	752797_20170927_S		752797_20170927_S	752797	9	IP	WCH	Adolescent 3	12	3	Paediatric	M	S	15.0	3.0	4.3	19.0	4.0	0.210526316	1.27	S. aureus; Candida albicans	0.0	0.0	1; 2; 6						77.0	77.0	85	0.905882353	2.0	1.0	Impaired	Yes	F508	F508	Third week admission - changed tob/taz to tob/ceftaz because PFTs still down	Yes	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, MSSA over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (PO augmentin since discharge, 3/52 since IV methylprednisolone x 1st course, >2/12 since IV ceftaz and tob)	Yes	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.378	SAGCFN_22_01792	1.06	CTGAAGCT	GTACTGAC	382	1.1
756934_20181205_S			756934_20181205_S	756934	443	IP	WCH	Adolescent 10	13	3	Paediatric	F	S								Oral flora; Candida albicans	0.0	0.0	2; 6		162.0	0.0	5.0	0.0	89.0	93.0	99	0.939393939	2.0	1.0	No	Yes	F508	G551D	2/52 admission for PA eradication	No	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-03-25	Yes	P. aeruginosa (x2) - fully sensitive. Tested positive for C. albicans, M. gordonae, A. fumigatus over next 12 months	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tazocin x 2 doses, about to commence IV ceftazidime)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.237	SAGCFN_22_01809	24.8	TCCGCGAA	TATAGCCT	392	2.9
756934_20181218_S	756934_20181218_S		756934_20181218_S	756934	456	IP	WCH	Level 6 Treatment	13	3	Paediatric	F	S								Oral flora; Candida albicans	0.0	0.0	2; 6						92.0	97.0	99	0.97979798	1.0	1.0	No	Yes	F508	G551D	2/52 admission for PA eradication	No	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-03-25	Yes	P. aeruginosa (x2) - fully sensitive. Tested positive for C. albicans, M. gordonae, A. fumigatus over next 12 months	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (2/52 of IV tazocin/ceftazidime)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	2	0	0	1.26	SAGCFN_22_01752	17.9	TCCGGAGA	GTACTGAC	498	3.8
768745_20171206_S			768745_20171206_S	768745	79	OP	WCH	Level 6 Treatment	11	3	Paediatric	F	S	0.0	1.0	3.5	0.0	2.0		1.48	Oral Flora	0.0	0.0	1						88.0	83.0	90	0.922222222	2.0	1.0	Impaired	Yes	F508	c.1393.2A>G	2/52 admission for acute on chronic bronchitis	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for MSSA over the next 12 months											1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	IV (2/52 of IV tob/taz)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.053	SAGCFN_22_01848	11.4	ACAACAGGCT	CAACAGTGGA	662	3.9
768745_20171123_S	768745_20171123_S		768745_20171123_S	768745	66	IP	WCH	Cassia 2	11	3	Paediatric	F	S	15.0	3.0	4.0	21.0	4.0	0.19047619	1.37	Oral Flora	0.0	0.0	1		48.0	0.0		0.0	87.0	85.0	90	0.94	2.0	1.0	Impaired	Yes	F508	c.1393.2A>G	2/52 admission for acute on chronic bronchitis	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for MSSA over the next 12 months											1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (about to receive IV tob/taz)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.323	SAGCFN_22_01798	12.2	TAATGCGC	TAATCTTA	598	3.1
768745_20190228_BAL			768745_20190228_BAL	768745	528	IP	WCH	DOSA	12	3	Paediatric	F	BAL								Oral flora (sputum); Oral flora (BAL) and Penicillium	0.0	0.0	0						76.0	72.0	85	0.84	3.0	1.0	Impaired	Yes	F508	c.1393.2A>G	Admitted for BAL for declining PFTs; October 2018 admission was for 3/52	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for MSSA over the next 12 months											1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Recent 4/52 of Aug Duo (ceased 1/52 prior)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	SAGCFN_22_01852	1.61	TGGAGATCGA	CATACCGCTG	351	1.3
768745_20190228_S			768745_20190228_S	768745	528	IP	WCH	DOSA	12	3	Paediatric	F	S								Oral flora (sputum); Oral flora (BAL) and Penicillium	0.0	0.0	0						76.0	72.0	85	0.84	3.0	1.0	Impaired	Yes	F508	c.1393.2A>G	Admitted for BAL for declining PFTs; October 2018 admission was for 3/52	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for MSSA over the next 12 months											1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Recent 4/52 of Aug Duo (ceased 1/52 prior)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.064	SAGCFN_22_01843	11.1	TCTCACCAGG	GACCTGTTAA	618	2.9
770590_20180115_S	770590_20180115_S		770590_20180115_S	770590	119	OP	WCH	Level 6 Treatment	11	3	Paediatric	F	S	9.0	2.0	2.9	17.0	4.0	0.235294118	1.89	Candida albicans	0.0	0.0	2; 9	Previous Bordetella species; A. flavus					106.0	109.0	111	0.981981982	1.0	1.0	No	Yes	F508	F508		No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0		No	Had tested positive to PA in previous 12 months; Tested positive for C. albicans, Achromobacter species over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0			0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	No (>2/12 since PO cipro + Inh tob ceased)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.06	SAGCFN_22_01755	33.4	CGCTCATT	CCTATCCT	576	3.3
770590_20170925_S	770590_20170925_S		770590_20170925_S	770590	7	OP	WCH	OPD 31a	11	3	Paediatric	F	S	10.0	2.0	3.3	17.0	3.0	0.176470588	1.66	Candida albicans	0.0	0.0	2; 9	Previous Bordetella species; A. flavus	33.0	0.0		0.0	96.0	93.0	111	0.837837838	3.0	1.0	No	Yes	F508	F508		No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0		No	Had tested positive to PA in previous 12 months; Tested positive for C. albicans, Achromobacter species over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0			0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	Yes (6/52 PO cipro + Inh tob, 2/52 of IV tob/ceftazidime prior)	Yes	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	4	0	0	0.643	SAGCFN_22_01774	16.1	ATTCAGAA	TAATCTTA	565	6.1
773911_20180130_S			773911_20180130_S	773911	134	OP	WCH	Lung Lab	11	3	Paediatric	M	S	18.0	3.0	2.3	43.0	7.0	0.162790698	2.39	Candida albicans	0.0	0.0	1; 2; 4; 6	Previous Klebsiella oxytoca; Mycobacterium mucogenicum; Mycobacterium abscessus; Mycobacterium scotochromogen	296.0	1.2		0.0	101.0	93.0	101	0.920792079	2.0	1.0	No	Yes	F508	621HG>T		Yes	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-04	Yes	MDR P. aeruginosa resistant to gentamicin, meropenem, intermediate to amikacin, sensitive to ceftazidime, cefipime, ciprofloxacin, piperacillin/tazobactam, tobramycin; Tested positive for C. albicans over next 12 months	1.0	1.0					1.0							0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	Yes (Inh tobramycin/PO cipro for 6/52; IV tob/ceftaz prior for 2/52)	Yes	1	1	1	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	4	4	0	0	0.143	SAGCFN_22_01826	7.08	AGCGATAG	ATAGAGGC	610	3.5
773911_20171213_S			773911_20171213_S	773911	86	IP	WCH	Cassia 17	11	3	Paediatric	M	S	10.0	2.0	3.9	14.0	3.0	0.214285714	1.41	Candida albicans	0.0	0.0	1; 2; 4; 6	Previous Klebsiella oxytoca; Mycobacterium mucogenicum; Mycobacterium abscessus; Mycobacterium scotochromogen					106.0	101.0	101	1.0	1.0	1.0	No	Yes	F508	621HG>T	2/52 admission for PA eradication (new best FEV1)	Yes	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-04	Yes	MDR P. aeruginosa resistant to gentamicin, meropenem, intermediate to amikacin, sensitive to ceftazidime, cefipime, ciprofloxacin, piperacillin/tazobactam, tobramycin; Tested positive for C. albicans over next 12 months	1.0	1.0					1.0							0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0	Yes (2/52 IV tob/ceftaz)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	0	0	0.105	SAGCFN_22_01834	17.9	ATAAGCGGAG	CGTAGAACAG	467	3.0
777599_20180306_S			777599_20180306_S	777599	169	IP	WCH	Cassia 17	11	3	Paediatric	F	S	13.0	3.0	4.6	15.0	4.0	0.266666667	1.19	Candida albicans	0.0	0.0	1; 6		138.0	0.0			95.0	81.0	104	0.778846154	3.0	2.0	No	Yes	F508	F508	2/52 admission for significant FEV1 drop	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-03-08	Yes	P. aeruginosa (MDR - R to amikacin, cefepime, ceftazidime, ciprofloxacin, meropenem, piperacillin/tazobactam, ticarcillin/clavulanate, tobramycin, S to gentamicin). Tested positive for A. fumigatus, Stenotrophomonas maltophilia, S. aureus over next 12 months	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1/7 Tob/Taz)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.236	SAGCFN_22_01810	35.6	TCCGCGAA	ATAGAGGC	348	2.2
778851_20171204_S	778851_20171204_S		778851_20171204_S	778851	77	OP	WCH	OPD 32	11	3	Paediatric	M	S	6.0	1.0	3.6	9.0	2.0	0.222222222	1.52	Candida albicans	0.0	0.0	1		345.0	13.0		2.0	99.0	97.0	101	0.96	1.0	1.0	No	Yes	F508	c.1340-26A>G		Unknown	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, MSSA over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (2/52 prior Aug duo)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.337	SAGCFN_22_01794	17.5	TAATGCGC	ATAGAGGC	600	5.0
778851_20180212_S			778851_20180212_S	778851	147	OP	WCH	OPD 34	11	3	Paediatric	M	S	20.0	4.0	4.0	27.0	5.0	0.185185185	1.37	S. aureus	0.0	0.0	1		300.0	20.0			95.0	97.0	101	0.96	1.0	1.0	No	Yes	F508	c.1340-26A>G		Unknown	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, MSSA over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (no antibiotics for 2/12)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.209	SAGCFN_22_01816	49.8	TCCGCGAA	GTACTGAC	402	2.2
778851_20170918_S			778851_20170918_S	778851	0	OP	WCH	OPD Rm33	11	3	Paediatric	M	S	27.0	5.0	3.5	42.0	8.0	0.19047619	1.57	Oral Flora	0.0	0.0	1						98.0	96.0	101	0.95049505	1.0	1.0	No	Yes	F508	c.1340-26A>G		Unknown	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, MSSA over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.127	SAGCFN_22_01829	23.3	AGCGATAG	AGGCGAAG	645	2.2
785991_20171206_S	785991_20171206_S		785991_20171206_S	785991	79	IP	WCH	Cassia 8	11	3	Paediatric	F	S	2.0	1.0	3.4	3.0	2.0	0.666666667	1.61	S. maltophilia; A. fumigatus	0.0	0.0	3; 6	Previous Acinetobacter species					60.0	54.0	65	0.830769231	3.0	1.0	Impaired	Yes	F508	F508	3 week admission; chronic steno infection; lung function remained low	No	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for Stenotrophomonas maltophilia, M. gordonae, A. fumigatus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	1.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	Yes (2/52 IV tob/taz)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.802	SAGCFN_22_01761	29.8	GAGATTCC	TATAGCCT	423	2.3
785991_20171129_S	785991_20171129_S		785991_20171129_S	785991	72	IP	WCH	Cassia 8	11	3	Paediatric	F	S	3.0	1.0	3.4	5.0	2.0	0.4	1.61	S. maltophilia	0.0	0.0	3; 6	Previous Acinetobacter species	88.0	2.6		2.0	49.0	43.0	65	0.661538462	3.0	2.0	Impaired	Yes	F508	F508	3 week admission; chronic steno infection	No	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for Stenotrophomonas maltophilia, M. gordonae, A. fumigatus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	1.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	IV tob/taz (6/7)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.789	SAGCFN_22_01763	28.8	GAGATTCC	CCTATCCT	487	2.0
785991_20171213_S			785991_20171213_S	785991	86	IP	WCH	Cassia 8	11	3	Paediatric	F	S	0.0	1.0	3.5	0.0	2.0		1.57	S. maltophilia; A. fumigatus	0.0	0.0	3; 6	Previous Acinetobacter species					62.0	55.0	65	0.846153846	3.0	1.0	Impaired	Yes	F508	F508	3 week admission; chronic steno infection; lung function remained low	No	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for Stenotrophomonas maltophilia, M. gordonae, A. fumigatus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	1.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	Yes (2/52 IV tob/taz, 1/52 IV tob/mero)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	3	3	0	0	0.111	SAGCFN_22_01832	24.4	AGCGATAG	GTACTGAC	646	3.1
785991_20180215_S			785991_20180215_S	785991	150	IP	WCH	Cassia 5	12	3	Paediatric	F	S	1.0	1.0	2.8	2.0	2.0	1.0	1.98	S. maltophilia; A. fumigatus	0.0	0.0	3; 6	Previous Acinetobacter species	78.0	2.3			42.0	36.0	57	0.631578947	3.0	2.0	Impaired	Yes	F508	F508	3 week admission for low lung function/persistent cough and recently diagnosed with ABPA	No	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for Stenotrophomonas maltophilia, M. gordonae, A. fumigatus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	1.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	Yes (Long-term PO bactrim, 1/7 IV methylprednisolone, 3/7 IV ceftazidime and tazocin)	Yes	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	3	4	0	1	0.12	SAGCFN_22_01831	26.2	AGCGATAG	CAGGACGT	630	2.0
785991_20180321_S	785991_20180321_S	785991_20180321_S	785991_20180321_S	785991	184	OP	WCH	Med Day unit 8	12	3	Paediatric	F	S	11.0	3.0	3.5	17.0	5.0	0.294117647	1.57	S. maltophilia	0.0	0.0	3; 6	Previous Acinetobacter species					56.0	49.0	57	0.859649123	3.0	1.0	Impaired	Yes	F508	F508	Methylprednisolone for ABPA	No	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for Stenotrophomonas maltophilia, M. gordonae, A. fumigatus	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	1.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	Yes (Long-term PO bactrim, 1/12 ago IV methylpred, 1 month of itraconazole)	Yes	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	1	3	1	1	6.29	SAGCFN_22_01739	31.2	ATTACTCG	CCTATCCT	668	4.4
788707_20180301_S	788707_20180301_S		788707_20180301_S	788707	164	IP	WCH	Cassia 9	11	3	Paediatric	M	S	16.0	3.0	4.3	20.0	4.0	0.2	1.27	Candida albicans	0.0	0.0	1; 6	Previous Enterobacter species	52.0	2.9		0.0	85.0	79.0	94	0.840425532	3.0	1.0	Yes	Yes	F508	F508	Readmitted following recent IV abx and ABPA treatment - 2/52 admission	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-11-16	Yes	S. aureus; P. aeruginosa (non-mucoid)	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	Yes (1/7 IV tobramycin, tazocin, long-term PO itraconazole, IV methylprednisolone 3/52 ago)	Yes	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	1	0	2	4	1	1	0.755	SAGCFN_22_01768	22.6	GAGATTCC	GTACTGAC	464	3.6
788707_20180308_S			788707_20180308_S	788707	171	IP	WCH	Cassia9	11	3	Paediatric	M	S	6.0	2.0	4.5	7.0	2.0	0.285714286	1.22	Candida albicans	0.0	0.0	1; 6	Previous Enterobacter species					88.0	86.0	94	0.914893617	2.0	1.0	Yes	Yes	F508	F508	Readmitted following recent IV abx and ABPA treatment - 2/52 admission	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-11-16	Yes	S. aureus; P. aeruginosa (non-mucoid)	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	Yes (8/7 IV tobramycin/IV tazocin, long-term PO itraconazole, 3/7 IV methylprednisolone ceased yesterday)	Yes	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	0	1	0	2	4	1	1	0.0177	SAGCFN_22_01850	3.48	TTCTCTTAGC	AGCTCGAGGA	407	2.9
788707_20180129_S			788707_20180129_S	788707	133	OP	WCH	OPD 33	11	3	Paediatric	M	S	41.0	7.0	4.0	56.0	10.0	0.178571429	1.37	A. fumigatus	0.0	0.0	1; 6	Previous Enterobacter species	143.0	9.0			85.0	81.0	94	0.861702128	3.0	1.0	Yes	Yes	F508	F508	Weaning prednisolone for ABPA - lung function did not improve much despite IV abx and pred	No	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-11-16	Yes	S. aureus; P. aeruginosa (non-mucoid)	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	Antifungal (Lozenoc 2 caps BD for 6/52), Prednisolone for 6/52 (weaning dose @ 25mg daily), Bactrim ceased 2/52 ago (4/52 course), no Ivs for 6/52	Yes	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	2	1	1	0.229	SAGCFN_22_01812	31.6	TCCGCGAA	GGCTCTGA	588	2.0
788707_20181116_S	788707_20181116_S		788707_20181116_S	788707	424	IP	WCH	Cassia 8	11	3	Paediatric	M	S								S. aureus; P. aeruginosa (non-mucoid)	0.0	1.0	1; 2; 3; 6	Previous Chryseobacterium indologenes; Aspergillus niger; Penicillium species	64.0	5.09	22.0		84.0	82.0	87	0.942528736	2.0	1.0	Yes	Yes	F508	F508	2/52 admission for PA eradication	No	0	1	1	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-11-16	Yes	S. aureus; P. aeruginosa (non-mucoid)	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	0	0	0	0	0	Yes (IV tazocin x 2 doses, about to commence IV tobramycin)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0.71	SAGCFN_22_01771	23.6	ATTCAGAA	CCTATCCT	541	3.7
788707_20181129_S			788707_20181129_S	788707	437	IP	WCH	Cassia 8	11	3	Paediatric	M	S								Candida albicans	0.0	0.0	1; 2; 3; 6	Previous Chryseobacterium indologenes; Aspergillus niger; Penicillium species					94.0	86.0	87	0.988505747	1.0	1.0	Yes	Yes	F508	F508	2/52 admission for PA eradication	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, S. aureus over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0		1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	Yes (IV tazocin/tobramycin x 2/52)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.282	SAGCFN_22_01802	34.6	CGGCTATG	ATAGAGGC	369	2.3
788707_20171213_S	788707_20171213_S		788707_20171213_S	788707	86	IP	WCH	Cassia 11	11	3	Paediatric	M	S	6.0	2.0	5.2	6.0	2.0	0.333333333	1.05	Candida albicans	0.0	0.0	1; 6	Previous Enterobacter species	151.0				68.0	60.0	94	0.638297872	3.0	2.0	Yes	Yes	F508	F508	2 week admission for acute on chronic bronchitis and diagnosed with ABPA	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-11-16	Yes	S. aureus; P. aeruginosa (non-mucoid)	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	Yes (1/52 of IV tob/taz)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.588	SAGCFN_22_01776	13.9	ATTCAGAA	GTACTGAC	476	5.9
788707_20180313_S	788707_20180313_S		788707_20180313_S	788707	176	OP	WCH	Cassia 9	11	3	Paediatric	M	S								Oral flora, Candida albicans, A. fumigatus	0.0	0.0	1;6	Previous Enterobacter species					89.0	87.0	94	0.925531915	2.0	1.0	Yes	Yes	F508	F508	Readmitted following recent IV abx and ABPA treatment - 2/52 admission	No	0	0	0	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0																2018-11-16	Yes	S. aureus; P. aeruginosa (non-mucoid)	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	Yes (2/52 of IV tobramycin/tazocin)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0.768	SAGCFN_22_01765	36.2	GAGATTCC	AGGCGAAG	409	1.5
802187_20180321_S			802187_20180321_S	802187	184	OP	WCH	Med Day Unit 9	10	2	Paediatric	F	S	9.0	2.0	4.2	12.0	3.0	0.25	1.3	Oral flora	0.0	0.0	1						96.0	101.0	103	0.98	1.0	1.0	No	Yes	F508	F508	FVC and FEV1 taken 8 days from sputum sample	Yes	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Oral flora only over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (IV methylprednisolone ¹ steroid therapy 1/12 prior)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0762	SAGCFN_22_01841	16.1	CGCACTTCGT	CTGGCATATT	489	4.3
802971_20180605_S	802971_20180605_S		802971_20180605_S	802971	260	IP	WCH	Cassia 6	10	2	Paediatric	F	S	28.0	11.0	3.8	40.0	16.0	0.4	1.44	P. aeruginosa (non-mucoid)	0.0	1.0	1; 2; 6	Previous P. aeruginosa (non-mucoid)	0.0	0.0	9.0	0.0	97.0	98.0	102	0.960784314	1.0	1.0	No	Yes	F508	2789delC	2/52 admission for acute on chronic bronchitis	No	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-05-21	Yes	P. aeruginosa - resistant to gentamicin, otherwise fully sensitive; Tested positive for C. albicans, MSSA over next 12 months	1.0						1.0				1.0			0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.517	SAGCFN_22_01781	10.8	GAATTCGT	AGGCGAAG	406	9.8
810653_20180115_S			810653_20180115_S	810653	119	OP	WCH	OPD 5	10	2	Paediatric	F	S	21.0	4.0	3.8	30.0	6.0	0.2	1.44	Oral Flora	0.0	0.0	1; 2						90.0	90.0	101	0.891089109	3.0	1.0	No	Yes	F508	F508		No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2020-06-01	No (over 12 months)	Tested positive for C. albicans, MSSA over next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.242	SAGCFN_22_01807	20.8	CGGCTATG	CAGGACGT	674	3.5
825012_20171206_S			825012_20171206_S	825012	79	IP	WCH	Cassia 18	9	2	Paediatric	M	S	2.0	11.0	4.8	2.0	13.0	6.5	1.14	Candida albicans	0.0	0.0	1						99.0	100.0	111	0.900900901	2.0	1.0	Impaired	Yes	F508	G85E	3/52 admission for weight loss and persistent clinical symptoms (very wet cough) - lung function declined during admission		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2022-01-31	No (over 12 months)	Tested positive for MSSA, C. albicans, A. terreus over the next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (2/52 of IV tob/taz)	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.147	SAGCFN_22_01825	27.6	AGCGATAG	TATAGCCT	623	2.2
825012_20181113_S			825012_20181113_S	825012	421	IP	WCH	Cassia 5	10	2	Paediatric	M	S								S. aureus	0.0	0.0	1	Previous A. terreus	580.0	4.9	158.0	1.0	96.0	93.0	104	0.894230769	3.0	1.0	Impaired	Yes	F508	G85E	3/52 admission for persistently low PFTs/cough		0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2022-01-31	No (over 12 months)	Tested positive for MSSA, C. albicans, A. terreus over the next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	Yes (IV tazocin x 2 doses, about to commence IV tobramycin and IV methylprednisolone)	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0.169	SAGCFN_22_01819	36.2	TCTCGCGC	CCTATCCT	474	0.4
825012_20181120_S	825012_20181120_S	825012_20181120_S	825012_20181120_S	825012	428	IP	WCH	Cassia 5	10	2	Paediatric	M	S								A. fumigatus	0.0	0.0	1	Previous A. terreus	542.0	6.0	145.0	1.0	89.0	87.0	104	0.836538462	3.0	1.0	Impaired	Yes	F508	G85E	3/52 admission for persistently low PFTs/cough - initial drop in FEV1		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2022-01-31	No (over 12 months)	Tested positive for MSSA, C. albicans, A. terreus over the next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	Yes (IV tazocin/tobramycin x 1/52 and completed x3/7 IV methylprednisolone)	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	2	3	0	1	2.13	SAGCFN_22_01745	20.0	TCCGGAGA	TATAGCCT	384	7.1
825012_20171123_S			825012_20171123_S	825012	66	IP	WCH	Cassia 17	9	2	Paediatric	M	S	10.0	22.0	3.8	14.0	32.0	2.285714286	1.44	S. aureus	0.0	0.0	1; 2		183.0	2.9		1.0	104.0	105.0	111	0.945945946	2.0	1.0	Impaired	Yes	F508	G85E	3/52 admission for weight loss and persistent clinical symptoms (very wet cough)	No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2022-01-31	No (over 12 months)	Tested positive for MSSA, C. albicans, A. terreus over the next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.296	SAGCFN_22_01799	33.4	TAATGCGC	CAGGACGT	417	2.6
825012_20181126_S	825012_20181126_S		825012_20181126_S	825012	434	IP	WCH	Cassia 5	10	2	Paediatric	M	S								Candida albicans	0.0	0.0	1; 6	Previous A. terreus	623.0	6.88	200.0	1.0	93.0	94.0	104	0.903846154	2.0	1.0	Impaired	Yes	F508	G85E	3/52 admission for persistently low PFTs/cough - initial drop in FEV1		0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2022-01-31	No (over 12 months)	Tested positive for MSSA, C. albicans, A. terreus over the next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	Yes (IV tazocin/tobramycin x 2/52 and completed x3/7 IV methylprednisolone the week before)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	2	3	0	1	0.733	SAGCFN_22_01769	23.6	ATTCAGAA	TATAGCCT	425	3.1
825012_20171129_S			825012_20171129_S	825012	72	IP	WCH	Cassia 18	9	2	Paediatric	M	S	11.0	7.0	4.2	14.0	9.0	0.642857143	1.3	S. aureus	0.0	0.0	1; 2		184.0	3.0		1.0	104.0	105.0	111	0.95	1.0	1.0	Impaired	Yes	F508	G85E	3/52 admission for weight loss and persistent clinical symptoms (very wet cough)	No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2022-01-31	No (over 12 months)	Tested positive for MSSA, C. albicans, A. terreus over the next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1/52 of IV tob/taz)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.0	SAGCFN_22_01855	0.344	ACCGAATAGA	CGGATGCTGA	468	0.2
848255_20190228_S			848255_20190228_S	848255	528	IP	WCH	DOSA	9	2	Paediatric	M	S								Oral flora; C. albicans; S. aureus (sputum); no growth BAL	0.0	0.0	1						95.0	98.0	98	1.0	1.0	1.0	No	Yes	F508	F508	2/52 admission for acute on chronic bronchitis	No	0	0	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for C. albicans, S. aureus over the next 12 months							1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (about to commence oral Augmentin)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0845	SAGCFN_22_01838	15.9	TCTAGCTGCG	CCTTACCTAT	593	3.0
875028_20180115_S	875028_20180115_S		875028_20180115_S	875028	119	OP	WCH	OPD 5	7	2	Paediatric	F	S	5.0	1.0	3.0	9.0	2.0	0.222222222	1.83	S. aureus; Lomentospora prolificans	0.0	0.0	2						121.0	114.0	114	1.0	1.0	1.0	No	Yes	F508	F508		No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-07	Yes	P. aeruginosa - resistant to gentamicin, amikacin, cefepime, sensitive to tobramycin, ciprofloxacin, piperacillin/tazobactam, meropenem; Tested positive for MSSA, Lomentospora prolificans, S. maltophilia over the next 12 months	1.0	1.0								1.0	1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Recently had 2/52 of aug duo (ceased 2/52 ago)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.461	SAGCFN_22_01786	20.8	CTGAAGCT	ATAGAGGC	602	3.3
877469_20190115_S			877469_20190115_S	877469	484	IP	WCH	Cassia 8	8	2	Paediatric	F	S								Oral flora; C. albicans	0.0	0.0	1		8.0	0.0	6.0	0.0	94.0	89.0	100	0.89	3.0	1.0	No	Yes	F508	F508	2/52 admission for acute on chronic bronchitis	No	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tob/taz x 1 dose)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	SAGCFN_22_01858	0.332	ATTCGGCTTA	CGGACGTTAA	383	0.2
892355_20180123_S	892355_20180123_S	892355_20180123_S	892355_20180123_S	892355	127	OP	RAH	Chest Clinic 6	49	7	Adult	F	S	0.0	1.0	4.0	0.0	1.0		1.37	S. aureus; S. apiospermum	0.0	0.0	1; 13						53.0	49.0	53	0.924528302	2.0	1.0	No	Yes	F508	p.q493x		Yes	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	2023-09-04	No (over 12 months)	Tested positive for S. aureus, Scedosporium apiospermum over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Azithromycin (long-term, M/W/F), Tobi inhaled (3 weeks), cephalexin (2 weeks), inner health probiotic, fluconazole 12 months ago	Yes	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	0	0	2.89	SAGCFN_22_01744	21.2	ATTACTCG	GTACTGAC	349	5.1
895293_20180502_S	895293_20180502_S		895293_20180502_S	895293	226	OP	RAH	TMO Lounge	47	7	Adult	F	S	18.0	8.0	4.1	24.0	11.0	0.458333333	1.34	P. aeruginosa (mucoid; mulitresistant)	0.0	1.0	2; 6		4.0	0.0	55.0	0.0			88				Yes	No	F508	G551D	No FVC or FEV1 taken close to sputum sample	No	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-05-02	Yes	MDR P. aeruginosa - resistant to everything except for cefipime, ceftazidime; Tested positive for C. albicans over next 12 months	1.0	1.0					1.0							0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (no Abx >2/12)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.442	SAGCFN_22_01787	16.9	CTGAAGCT	CCTATCCT	584	4.6
896213_20180427_S			896213_20180427_S	896213	221	OP	WCH	Level 6 Treatment	6	1	Paediatric	F	S	10.0	5.0	3.8	14.0	7.0	0.5	1.44	A. fumigatus	0.0	0.0	1; 6						97.0	99.0	107	0.925233645	2.0	1.0	No	Yes	F508	F508	2 week admission for acute on chronic bronchitis and drop in FEV1	No	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for A. fumigatus over the next 12 months									1.0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (10/7 IV tobramycin/tazocin)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0.0	SAGCFN_22_01854	0.436	CCACAGCCTT	CTTCAATAGC	477	0.2
913873_20180417_S			913873_20180417_S	913873	211	IP	WCH	Cassia 17	6	1	Paediatric	F	S	9.0	4.0	4.1	12.0	5.0	0.416666667	1.34	Oral flora	0.0	0.0	8; 14		18.0	0.0	4.0	0.0	100.0	80.0	98	0.816326531	3.0	1.0	No	Yes	F508	F508	2 week admission for acute on chronic bronchitis	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0		No (over 12 months)	Tested positive for C. albicans over next 12 months							1.0							0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (about to commence IV antibiotics - tobramycin and tazocin)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	SAGCFN_22_01853	0.162	CCAGACCGAT	TGCAAGTAGC	863	0.0
980574_20180403_S			980574_20180403_S	980574	197	OP	RAH	Chest Clinic 3	44	6	Adult	M	S	3.0	1.0	2.9	6.0	2.0	0.333333333	1.89	P. aeruginosa (non-mucoid; multiresistant)	0.0	1.0	2	Previous P. aeruginosa (mucoid; non-mucoid; multiresistant)					74.0	67.0	69	0.971014493	1.0	1.0	No	Yes	F508	F508		No	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-03	Yes	MDR P. aeruginosa - resistant to everything except for piperacillin/tazobactam; Tested positive for C. albicans, M. avium complex over the next 12 months	1.0	1.0			1.0		1.0							0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	Yes (long-term inhaled tobramycin/inhaled colistin alternating monthly)	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.216	SAGCFN_22_01814	34.6	TCCGCGAA	TAATCTTA	364	2.2
983493_20180123_S	983493_20180123_S		983493_20180123_S	983493	127	OP	RAH	Chest Clinic 3	46	7	Adult	F	S	2.0	1.0	4.0	3.0	1.0	0.333333333	1.37	P. aeruginosa (multi-resistant; mucoid)	0.0	1.0	2; 6	Previous mucoid and non-mucoid P. aeruginosa	12.0	0.92		2.0	58.0	54.0	57	0.947368421	2.0	1.0	No	Yes	F508	F508		No	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-01-23	Yes	MDR P. aeruginosa - resistant to ceftazidime, gentamicin, sensitive to ciprofloxacin, piperacillin/tazobactam; Tested positive for C. albicans, S. maltophilia over next 12 months	1.0	1.0					1.0			1.0				0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	Yes (augmentin for past 3 weeks)	Yes	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.698	SAGCFN_22_01773	21.6	ATTCAGAA	AGGCGAAG	469	4.4
1068841_20180306_S	1068841_20180306_S		1068841_20180306_S	1068841	169	OP	RAH	Chest Clinic 7	47	7	Adult	M	S	14.0	3.0	3.8	20.0	4.0	0.2	1.44	A. niger; A. terreus	0.0	0.0	6	Previous A. niger					98.0	95.0	98	0.969387755	1.0	1.0	No	Yes	F508	?		No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-08	Yes	P. aeruginosa  - fully sensitive ; Tested positive for MSSA, A. terreus complex, A. niger, A. flavus, C. albicans, Penicillium species over the next 12 months	1.0						1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	No (No antibiotics for >2/12)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.07	SAGCFN_22_01754	42.8	CGCTCATT	ATAGAGGC	417	2.8
1085876_20180227_S			1085876_20180227_S	1085876	162	OP	RAH	Chest Clinic 6	40	6	Adult	F	S	1.0	1.0	2.9	2.0	2.0	1.0	1.89	P. aeruginosa (non-mucoid)	0.0	1.0	2; 6						71.0	64.0	67	0.955223881	1.0	1.0	No	Yes	F508	F508		No	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-02-27	Yes	P. aeruginosa x 2 (1 x fully sensitive, 1 x mucoid resistant to amikacin, gentamicin, S - everything else); Tested positive for A. fumigatus over the next 12 months	1.0	1.0	1.0						1.0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (long-term Azithromycin)	Yes	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.132	SAGCFN_22_01828	19.0	AGCGATAG	GGCTCTGA	674	2.5
1128691_20171206_S			1128691_20171206_S	1128691	79	IP	RAH	RAH 8E 05	47	7	Adult	F	S	2.0	1.0	4.0	3.0	1.0	0.333333333	1.37	P. aeruginosa (mucoid)	0.0	1.0	2; 6						38.0	29.0	33	0.878787879	3.0	1.0	No	Yes	F508	F508	Listed for lung transplant	Yes	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2017-12-06	Yes	Mucoid P. aeruginosa resistant to amikacin, gentamicin, tobramycin, sensitive to ciprofloxacin, ceftazidime, meropenem, piperacillin/tazobactam; Tested positive for C. albicans, A. fumigatus over next 12 months	1.0	1.0	1.0				1.0		1.0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	IV meropenem 2g TDS, IV tobramycin 360mg daily (3/7), PO azithromycin and alt. Inh Tob/Coli long-term	Yes	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	1	3	3	0	0	1.75	SAGCFN_22_01748	33.4	TCCGGAGA	GGCTCTGA	535	4.5
1128691_20180116_S	1128691_20180116_S		1128691_20180116_S	1128691	120	OP	RAH	Chest Clinic 4	47	7	Adult	F	S	0.0	1.0	3.0	0.0	2.0		1.83	P. aeruginosa (mucoid); A. fumigatus	0.0	1.0	2; 6	Previous Penicillium species					34.0	27.0	33	0.818181818	3.0	1.0	No	Yes	F508	F508	Listed for lung transplant		1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-01-16	Yes	Mucoid P. aeruginosa resistant to amikacin, gentamicin, tobramycin, sensitive to ciprofloxacin, ceftazidime, meropenem, piperacillin/tazobactam; Tested positive for C. albicans, A. fumigatus over next 12 months	1.0	1.0	1.0				1.0		1.0					1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1/12 of inhaled tobramycin (preceded by 2 weeks of IV abx)	Yes	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0.708	SAGCFN_22_01772	27.4	ATTCAGAA	GGCTCTGA	500	3.8
1128691_20171218_S	1128691_20171218_S	1128691_20171218_S	1128691_20171218_S	1128691	91	OP	RAH	Chest Clinic 1	47	7	Adult	F	S	1.0	1.0	3.4	2.0	2.0	1.0	1.61	P. aeruginosa (mucoid); Penicillium species	0.0	1.0	2; 6						36.0	31.0	33	0.939393939	2.0	1.0	No	Yes	F508	F508	Completed 2/52 admission; listed for lung transplantation		1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2017-12-18	Yes	Mucoid P. aeruginosa resistant to amikacin, gentamicin, tobramycin, sensitive to ciprofloxacin, ceftazidime, meropenem, piperacillin/tazobactam; Tested positive for C. albicans, A. fumigatus over next 12 months	1.0	1.0	1.0				1.0		1.0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	IV Tobramycin/Meropenem (2/52)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	3.4	SAGCFN_22_01743	30.8	ATTACTCG	CAGGACGT	352	4.8
1282052_20180206_S	1282052_20180206_S		1282052_20180206_S	1282052	141	OP	RAH	Chest Clinic 4	33	5	Adult	M	S	15.0	3.0	3.2	26.0	5.0	0.192307692	1.71	S. aureus; P. aeruginosa (multiresistant; mucoid)	0.0	1.0	0						54.0	48.0	52	0.923076923	2.0	1.0	No	Yes	F508	F508		No	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-02-06	Yes	MDR P. aeruginosa - resistant to amikacin, gentamicin, cefipime, meropenem - sensitive to ciprofloxacin, tobramycin, ceftazidime, piperacillin/tazobactam; Tested positive for MSSA, C. albicans over the next 12 months	1.0	1.0					1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (Inh colistin long-term, long-term PO azithromycin ceased 1/12 ago)	Yes	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0.514	SAGCFN_22_01783	30.2	GAATTCGT	CAGGACGT	525	2.9
1316935_20180417_S	1316935_20180417_S		1316935_20180417_S	1316935	211	OP	RAH	Chest Clinic 4	33	5	Adult	M	S	6.0	3.0	2.0	17.0	8.0	0.470588235	2.75	P. aeruginosa (mucoid; mulitresistant)	0.0	1.0	1; 2	Previous P. aeruginosa (mucoid; non-mucoid; multiresistant)					93.0	84.0	104	0.807692308	3.0	1.0	No	Yes	F508	F508		No	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-17	Yes	MDR P. aeruginosa - resistant to everything except for piperacillin/tazobactam; Tested positive for A. niger over the next 12 months	1.0	1.0												0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (long-term inhaled tobramycin/inhaled colistin alternating monthly)	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.796	SAGCFN_22_01762	21.6	GAGATTCC	ATAGAGGC	509	2.4
1447437_20171006_S	1447437_20171006_S		1447437_20171006_S	1447437	18	OP	RAH	Chest Clinic 4	31	5	Adult	M	S	23.0	4.0	3.6	35.0	6.0	0.171428571	1.52	P. aeruginosa (?species with oral flora contamination)	0.0	1.0	2						76.0	72.0	74	0.972972973	1.0	1.0	No	Yes	F508	?	Subacute colitis and abdominal pain	No	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2017-10-06	Yes	Pseudomonas species. Tested positive for MSSA, P. aeruginosa, C. albicans over next 12 months	1.0						1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (long-term inhaled tobramycin/inhaled colistin alternating monthly)	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.515	SAGCFN_22_01782	26.2	GAATTCGT	TAATCTTA	614	2.9
1447437_20171212_S	1447437_20171212_S		1447437_20171212_S	1447437	85	OP	RAH	Chest Clinic 4	31	5	Adult	M	S	20.0	3.0	3.3	33.0	5.0	0.151515152	1.66	S. aureus; P. aeruginosa (x 2 strains; 1 mucoid)	0.0	1.0	2		3.0	0.0		0.0	74.0	68.0	74	0.918918919	2.0	1.0	No	Yes	F508	?	No CF exacerbation for >12 months	No	1	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2017-10-06	Yes	Mucoid P. aeruginosa - intermediate to amikacin, S - everything else. Tested positive for MSSA, P. aeruginosa, C. albicans over next 12 months	1.0		1.0				1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.51	SAGCFN_22_01750	32.6	TCCGGAGA	TAATCTTA	498	4.7
1465461_20180406_S			1465461_20180406_S	1465461	200	OP	RAH	Chest Clinic 3	31	5	Adult	M	S	22.0	5.0	3.2	38.0	9.0	0.236842105	1.71	P. aeruginosa (mucoid; non-mucoid; multiresistant)	0.0	1.0	0						114.0	94.0	102	0.92	2.0	1.0	No		F508	G551D		No	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-06	Yes	MDR P. aeruginosa - resistant to everything; Tested positive for C. albicans over next 12 months	1.0	1.0					1.0							0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (no antibiotics for >2/12)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.246	SAGCFN_22_01806	18.6	CGGCTATG	TAATCTTA	546	6.0
1470026_20180502_S	1470026_20180502_S		1470026_20180502_S	1470026	226	IP	RAH	RAH 8E 07	23	4	Adult	M	S	1.0	2.0	4.0	1.0	3.0	3.0	1.37	S. maltophilia; C. albicans	0.0	0.0	1; 2; 6; 8						76.0	62.0	78	0.794871795	3.0	2.0	No	Yes	F508	F508	2/52 admission for acute on chronic bronchitis	No	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for Stenotrophomonas maltophilia, A. fumigatus, C. albicans, S. aureus over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	1.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1/7 of IV tobramycin/IV cefopime, preceded by 1/52 of Inh Tob/PO cipro)	Yes	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	3	0	0	0.487	SAGCFN_22_01784	24.8	GAATTCGT	GTACTGAC	647	2.6
1565754_20180403_S	1565754_20180403_S		1565754_20180403_S	1565754	197	OP	RAH	Chest Clinic 5	25	5	Adult	F	S	13.0	3.0	3.0	24.0	5.0	0.208333333	1.83	P. aeruginosa (mucoid; mulitresistant)	0.0	1.0	2						81.0	73.0	78	0.935897436	2.0	1.0	No	Yes	F508	?	Recent exacerbation and next exacerbation in 2/12	No	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2017-11-28	Yes	Mucoid P. aeruginosa resistant to amikacin, gentamicin, tobramycin, sensitive to ciprofloxacin, ceftazidime, meropenem, piperacillin/tazobactam; Tested positive for MSSA, C. albicans, A. fumigatus,  MRD P. aeruginosa, over the next 12 months	1.0	1.0	1.0				1.0		1.0		1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (recent 2/52 IV tob/mero 1/12 ago)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.953	SAGCFN_22_01758	34.8	CGCTCATT	TAATCTTA	519	3.6
1565754_20171128_S	1565754_20171128_S	1565754_20171128_S	1565754_20171128_S	1565754	71	OP	RAH	Chest Clinic 7	25	5	Adult	F	S	7.0	2.0	3.4	11.0	3.0	0.272727273	1.61	P. aeruginosa (mucoid); S. aureus; A. fumigatus	0.0	1.0	2						82.0	75.0	78	0.961538462	1.0	1.0	No	Yes	F508	?	Next CF exacerbation in 3/12	No	1	0	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-03	Yes	MDR P. aeruginosa resistant to amikacin, gentamicin, tobramycin, ciprofloxacin, sensitive to ceftazidime, meropenem, piperacillin/tazobactam; Tested positive for MSSA, C. albicans, A. fumigatus,  MRD P. aeruginosa, over the next 12 months	1.0	1.0	1.0				1.0		1.0		1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (recent IV tobramycin/tazocin 1/12 ago)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.03	SAGCFN_22_01740	26.2	ATTACTCG	GGCTCTGA	473	5.8
1586713_20180309_S	1586713_20180309_S		1586713_20180309_S	1586713	172	IP	RAH	8E Rm06	25	5	Adult	M	S	54.0	11.0	4.6	64.0	13.0	0.203125	1.19	Candida albicans	0.0	0.0	1; 2	Previous P. aeruginosa (mucoid)					81.0	73.0	77	0.948051948	2.0	1.0	No		F508	?		No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-11-02	Yes	P. aeruginosa - fully sensitive; Tested positive for C. albicans, MRSA over the next 12 months	1.0						1.0				1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	Yes (12/7 IV tobramycin + IV ceftazidime)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.809	SAGCFN_22_01760	29.6	CGCTCATT	GTACTGAC	420	3.9
1588281_20180508_S	1588281_20180508_S		1588281_20180508_S	1588281	232	OP	RAH	Chest Clinic 6	26	5	Adult	M	S	7.0	2.0	3.2	12.0	3.0	0.25	1.71	P. aeruginosa (mucoid, multi-resistant); C. albicans	0.0	1.0	2						111.0	109.0	114	0.956140351	1.0	1.0	No	Yes	F508	F508		No	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-05-08	Yes	P. aeruginosa - resistant to amikacin, ciprofloxacin, gentamicin, sensitive - tobramycin, meropenem, cefipime, ceftazidime, piperacillin/tazobactam; Tested positive for C. albicans, MDR P. aeruginosa over next 12 months	1.0	1.0					1.0							0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (Long-term azithromycin 3x week, IV abx 6/52 ago)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.712	SAGCFN_22_01770	35.8	ATTCAGAA	ATAGAGGC	548	1.8
1590009_20171212_S	1590009_20171212_S		1590009_20171212_S	1590009	85	OP	RAH	Chest Clinic 1	29	5	Adult	M	S	12.0	2.0	4.4	15.0	3.0	0.2	1.25	S. aureus	0.0	0.0	1						89.0	87.0	92	0.945652174	2.0	1.0	No	Yes	F508	?		No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-12	Yes	Mucoid P. aeruginosa - fully sensitive; Tested positive for MSSA over the next 12 months	1.0	1.0									1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.67	SAGCFN_22_01749	39.8	TCCGGAGA	AGGCGAAG	401	3.8
1593967_20180424_S	1593967_20180424_S		1593967_20180424_S	1593967	218	IP	WCH	Chest Clinic 6	29	5	Adult	M	S	5.0	2.0	4.5	5.0	2.0	0.4	1.22	P. aeruginosa (mucoid; non-mucoid; multiresistant)	0.0	1.0	2	Previous P. aeruginosa (mucoid; non-mucoid; multiresistant)					82.0	71.0	76	0.934210526	2.0	1.0	Yes	Yes	F508	F508		No	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-27	Yes	MDR P. aeruginosa - resistant to everything. Tested positive for C. albicans over next 12 months	1.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	No (ceased inhaled Tob 2/52 - month on/off regimen)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.19	SAGCFN_22_01753	35.8	CGCTCATT	TATAGCCT	364	3.1
1593973_20180504_S	1593973_20180504_S	1593973_20180504_S	1593973_20180504_S	1593973	228	OP	RAH	Chest Clinic 1	30	5	Adult	M	S	12.0	5.0	2.8	24.0	10.0	0.416666667	1.96	P. aeruginosa (mucoid; multidrug resistant); Candida albicans	0.0	1.0	2	Previous Proteus mirabilis, A. niger, and penicillium species	408.0	4.1	17.0	0.0	101.0	98.0	104	0.94	2.0	1.0	No	Yes	F508	F508	2 week admission for acute on chronic bronchitis	No	1	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-05-04	Yes	MDR P. aeruginosa - resistant to everything except for piperacillin/tazobactam. Tested positive for C. albicans over next 12 months	1.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	Yes (Long-term inhaled tobramycin alternating)	Yes	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	2.05	SAGCFN_22_01746	8.66	TCCGGAGA	ATAGAGGC	532	13.3
1593973_20180427_S	1593973_20180427_S		1593973_20180427_S	1593973	221	OP	RAH	Chest Clinic 6	30	5	Adult	M	S	7.0	4.0	2.7	14.0	8.0	0.571428571	2.03	P. aeruginosa (multi-resistant)	0.0	1.0	2	Previous Proteus mirabilis, A. niger, and penicillium species					103.0	92.0	104	0.884615385	3.0	1.0	No	Yes	F508	F508	2 week admission for acute on chronic bronchitis	No	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-27	Yes	MDR P. aeruginosa - resistant to everything. Tested positive for C. albicans over next 12 months	1.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	Yes (inhaled tobramycin for past 3 weeks)	Yes	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0.889	SAGCFN_22_01759	16.5	CGCTCATT	CAGGACGT	357	7.7
1651490_20171010_S	1651490_20171010_S	1651490_20171010_S	1651490_20171010_S	1651490	22	OP	RAH	Chest Clinic 3	26	5	Adult	F	S	11.0	3.0	3.5	17.0	5.0	0.294117647	1.57	S. aureus	0.0	0.0	1; 6	Previous penicillium; talaromyces purpurogenus; A. niger					75.0	69.0	74	0.932432432	2.0	1.0	No	Yes	F508	F508	No exacerbation for 6 months	No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-09-04	Yes	S. aureus, C. albicans, P. aeruginosa (non-mucoid R to gentamicin, amikacin, S to all others)	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	18.0	SAGCFN_22_01737	30.6	ATTACTCG	TATAGCCT	363	4.9
1651490_20180206_S	1651490_20180206_S	1651490_20180206_S	1651490_20180206_S	1651490	141	OP	RAH	Chest Clinic 1	27	5	Adult	F	S	7.0	2.0	3.3	12.0	3.0	0.25	1.66	S. aureus	0.0	0.0	1; 6						72.0	66.0	74	0.891891892	3.0	1.0	No	Yes	F508	F508	Exacerbation in 1 month		0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-09-04	Yes	S. aureus, C. albicans, P. aeruginosa (non-mucoid R to gentamicin, amikacin, S to all others)	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (ceased inhaled tobramycin >1/12 ago)	No	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	4.76	SAGCFN_22_01741	26.2	ATTACTCG	AGGCGAAG	507	6.4
1651490_20171215_S	1651490_20171215_S	1651490_20171215_S	1651490_20171215_S	1651490	88	OP	RAH	Chest Clinic 4	26	5	Adult	F	S	18.0	4.0	3.7	27.0	6.0	0.222222222	1.48	S. aureus	0.0	0.0	1; 6	Previous A. niger					74.0	72.0	74	0.972972973	1.0	1.0	No	Yes	F508	F508	CF exacerbation in 3 months		0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-09-04	Yes	S. aureus, C. albicans, P. aeruginosa (non-mucoid R to gentamicin, amikacin, S to all others)	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	Inhaled Tobramycin (2/52)	Yes	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	7.76	SAGCFN_22_01738	34.2	ATTACTCG	ATAGAGGC	564	6.0
1658447_20171006_S			1658447_20171006_S	1658447	18	OP	RAH	Chest Clinic 3	26	5	Adult	M	S	1.0	1.0	4.4	1.0	1.0	1.0	1.25	P. aeruginosa (mucoid)	0.0	1.0	2	Previous penicillium					99.0	92.0	96	0.958333333	1.0	1.0	No	Yes	F508	F508	Next CF exacerbation 9 months	Yes	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2017-10-06	Yes	Mucoid P. aeruginosa - resistant to amikacin, gentamicin, ciprofloxacin, I - meropenem, S - tobramycin. Tested positive for MDR P. aeruginosa over next 12 months piperacillin/tazobactam, ceftazidime	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (recent inhaled ceftazidime 2/52 ago)	Yes	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.098	SAGCFN_22_01837	13.1	CAGCAGGTCA	TACCTAAGTG	576	2.9
1664053_20180406_S			1664053_20180406_S	1664053	200	OP	RAH	Chest Clinic 1	26	5	Adult	F	S	9.0	3.0	4.6	11.0	4.0	0.363636364	1.19	S. aureus; P. aeruginosa (non-mucoid)	0.0	1.0	0						88.0	84.0	88	0.954545455	1.0	1.0	No	Yes	F508	F508	Not fasted for >4 hours (mueslie and yoghurt ~3 hours prior)	No	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-06	Yes	P. aeruginosa (mucoid, resistant - amikacin, cefipime, tobramycin, gentamicin, sensitive - ceftazidime, ciprofloxacin, meropenem) ; Tested positive for MSSA, Penicillium species over the next 12 months	1.0	1.0	1.0								1.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (PO azithromycin daily, finished inhaled colistin yesterday [month on/off regimen])	Yes	0	1	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	3	3	1	0	0.159	SAGCFN_22_01822	30.8	TCTCGCGC	TAATCTTA	374	1.9
1690154_20180406_S			1690154_20180406_S	1690154	200	OP	RAH	Chest Clinic 4	25	5	Adult	M	S	67.0	16.0	5.7	65.0	16.0	0.246153846	0.97	S. aureus; P. aeruginosa (non-mucoid); A. fumigatus	0.0	1.0	1; 2; 6	Previous P. aeruginosa (non-mucoid; mucoid; multiresistant)					86.0	75.0	78	0.961538462	1.0	1.0	No	Yes	F508	?	Not fasted for >4 hours (iced coffee ~3 hours prior)	No	0	1	1	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-04-06	Yes	P. aeruginosa - fully sensitive; Tested positive for MSSA, C. albicans, A. fumigatus over the next 12 months	1.0						1.0		1.0					0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	No (ceased inhaled Tob 2/52 - month on/off regimen)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.276	SAGCFN_22_01804	35.0	CGGCTATG	GGCTCTGA	648	3.1
1834617_20180501_S	1834617_20180501_S		1834617_20180501_S	1834617	225	OP	RAH	Chest Clinic 8	21	4	Adult	F	S	5.0	2.0	3.6	8.0	3.0	0.375	1.52	S. aureus	0.0	0.0	1		15.0	0.26	105.0	1.0	91.0	84.0	88	0.954545455	1.0	1.0	Yes	Yes	F508	?		No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for S. aureus, C. albicans over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (1 dose of inhaled tobramycin 3/7 ago, IV Abx 2/12 ago)	Yes	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0.43	SAGCFN_22_01790	17.0	CTGAAGCT	TAATCTTA	545	4.8
1845116_20180403_S	1845116_20180403_S		1845116_20180403_S	1845116	197	OP	RAH	Chest Clinic 1	28	5	Adult	M	S								S. aureus	0.0	0.0	1						97.0	93.0	97	0.958762887	1.0	1.0	No	Yes	F508	F508		No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for S. aureus, C. albicans over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.767	SAGCFN_22_01766	27.6	GAGATTCC	TAATCTTA	407	3.2
1862551_20180123_S			1862551_20180123_S	1862551	127	OP	RAH	Chest Clinic 3 Exam	22	4	Adult	M	S	15.0	3.0	5.2	16.0	3.0	0.1875	1.05	Candida albicans	0.0	0.0	3; 6		173.0				85.0	82.0	84	0.976190476	1.0	1.0	Yes	Yes	F508	G551D			0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	 Tested positive for C. albicans, Penicillium species, M. chelonae over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Ate cheese toast and lemonade 3 hours prior (IV abx 1/52 of IV tob/cefapime and 10 days prior IV ceftazidime and neb tob; PO lozenoc 3/7 and PO prednisolone 1/52) on Kalydeco	Yes	1	1	1	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	1	3	6	1	2	0.207	SAGCFN_22_01817	33.4	TCTCGCGC	TATAGCCT	499	1.5
642660_20180601_S	642660_20180601_S		642660_20180601_S	642660	256	IP	WCH	Adol Rm 11	17	3	Paediatric	F	S	22.0	8.0	3.8	32.0	12.0	0.375	1.44	Oral flora; C. albicans; M. abscessus; M. intracellulare	1.0	0.0	2; 4; 5						92.0	91.0	91	1.0	1.0	1.0	No	Yes	F508	F508	3/12 admission for NTM	No	0	0	0	1	0	0	0	1	1	1	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-09	Yes	P. aeruginosa (MDR - R to ceftazidime, ciprofloxacin, gentamicin, piperacillin/tazobactam, I to  amikacin, S - to all others). Had tested positive in previous 12 months; Over next 12 months tested positive for MDR Pseudomonas aeruginosa/Mycobacterium intracellulare/Mycobacterium abscessus/Candida albicans; Tested positive for MDR Pseudomonas again in November 2018 (but multiple negative in between)	1.0	1.0	0.0	0.0	1.0	1.0	1.0	0.0	0.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (PO cipro/Inh tob for 2/12, IV antiPA anitbiotics 2/12 prior; just prior to commencing IV abx vs NTM)	Yes	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	0	0	0.538	SAGCFN_22_01780	21.8	GAATTCGT	GGCTCTGA	491	4.8
670829_20171005_S			670829_20171005_S	670829	17	IP	WCH	Adolescent 6	15	3	Paediatric	F	S	8.0	2.0	3.8	12.0	3.0	0.25	1.44	Oral Flora	0.0	0.0	1; 4; 6	Previous A. flavus growth; NTM = M. abscessus; Cupriavidus gilardii					108.0	110.0	125	0.88	3.0	1.0	No	Yes	F508	F508	3/12 IV NTM admission (complicated by allergy to cefoxitin)	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-11	No (over 12 months)	Tested positive for A. fumigatus, A. flavus, M. abscessus over next 12 months	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0				0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV amikacin for 7 days, IV cefoxitin for 3 days)	Yes	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.102	SAGCFN_22_01836	5.16	ATGTTGCCAC	ATGGCTTCTA	668	4.0
670829_20180201_S			670829_20180201_S	670829	136	IP	WCH	Day Surgery 17	16	3	Paediatric	F	S	87.0	12.0	3.2	149.0	21.0	0.140939597	1.71	A. fumigatus	0.0	0.0	1; 4; 6	Previous A. flavus growth; NTM = M. abscessus; Cupriavidus gilardii					114.0	117.0	125	0.936	2.0	1.0	No	Yes	F508	F508	End of 3 month admission for NTM eradication	No	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-11	Yes	P. aeruginosa (non-mucoid, fully sensitive)	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0				0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (Inh amikacin, PO azithro, PO clofazamine [2 months], PO lozenoc and PO prednisolone [1 month], Multiple IV and Oral agents 2/12 ago)	Yes	0	1	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	2	1	0	0.081	SAGCFN_22_01840	8.58	AGGTAACAAC	AGCATCGTGC	469	3.1
670829_20170922_S			670829_20170922_S	670829	4	IP	WCH	Adolescent 6	15	3	Paediatric	F	S	59.0	10.0	3.7	87.0	15.0	0.172413793	1.48	Oral Flora	0.0	0.0	1; 4; 6	Previous A. flavus growth; NTM = M. abscessus; Cupriavidus gilardii	301.0	5.8		1.0	96.0	99.0	125	0.79	3.0	2.0	No	Yes	F508	F508	At start of 3/12 IV NTM eradication; FVC and FEV1 taken 6 days from sputum sample	No	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-11	No (over 12 months)	Tested positive for A. fumigatus, A. flavus, M. abscessus over next 12 months	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0				0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (about to commence IV NTM eradication - cefoxitin, amikacin, azithromycin, clofazamine)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.063	SAGCFN_22_01845	8.56	TCGAACACGA	AGAACCTCGC	660	2.7
698564_20171001_S			698564_20171001_S	698564	13	IP	WCH	Adolescent 2	14	3	Paediatric	F	S	0.0	0.0	3.8	0.0	0.0		1.44	P. aeruginosa	0.0	1.0	2; 3		891.0	52.0		2.0	74.0	59.0	70	0.842857143	3.0	1.0	No	Yes	F508	F508		Yes	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-12-05	Yes	S. maltophilia; P. aeruginosa (?aeruginosa); Unclassified rapid NTM (smear negative)	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	1.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (about to commence IV tob/taz)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	SAGCFN_22_01862	0.874	GCCAGCTATC	ACACGAACAA	313	0.7
698564_20180215_S			698564_20180215_S	698564	150	IP	WCH	Adol 5	14	3	Paediatric	F	S	1.0	1.0	3.9	1.0	1.0	1.0	1.41	Candida albicans	0.0	0.0	2; 3		732.0	36.0		0.0	80.0	68.0	70	0.971428571	1.0	1.0	No	Yes	F508	F508		Yes	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-12-05	Yes	S. maltophilia; P. aeruginosa (?aeruginosa); Unclassified rapid NTM (smear negative)	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	1.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (8/7 IV tobramycin and IV tazocin, 1/7 IV methylprednisolone)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	2	3	0	1	0.0	SAGCFN_22_01851	1.1	TCGCGACACT	ACATTACTCG	393	0.5
698917_20171207_S	698917_20171207_S		698917_20171207_S	698917	80	OP	WCH	Day Surgery 17	14	3	Paediatric	F	S	45.0	7.0	4.8	51.0	8.0	0.156862745	1.14	M. abscessus (on BAL; no smear); S. aureus (on sputum)	1.0	0.0	1; 4; 6	Previous M. abscessus							106				No	Yes	F508	C743+415,C1584+2987	Admitted for BAL to assess for NTM - then commenced eradication a few weeks later; No FVC or FEV1 taken within 4 weeks of of sputum sample	No	0	0	0	0	0	0	0	0	1	0	1	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-14	Yes	P. aeurignosa x 2 (MDR - R to amikacin, cefepime, ciprofloxacin, gentamicin, meropenem, piperacillin/tazobactam, S to ceftazidime, tobramycin; mucoid - R to amikacin, cefepime, gentamicin, S - to all others	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	PO Aug Duo (3/52)	Yes	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.435	SAGCFN_22_01788	16.6	CTGAAGCT	GGCTCTGA	433	4.7
698917_20180119_S	698917_20180119_S		698917_20180119_S	698917	123	IP	WCH	Adol Room 1	14	3	Paediatric	F	S	95.0	13.0	4.2	124.0	17.0	0.137096774	1.3	Candida albicans	0.0	0.0	1; 4; 6		67.0	0.71		2.0	103.0	104.0	106	0.981132075	1.0	1.0	No	Yes	F508	C743+415,C1584+2987	Admission for NTM eradication - 3/12 therapy IV	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-14	Yes	P. aeurignosa x 2 (MDR - R to amikacin, cefepime, ciprofloxacin, gentamicin, meropenem, piperacillin/tazobactam, S to ceftazidime, tobramycin; mucoid - R to amikacin, cefepime, gentamicin, S - to all others	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1/52 of NTM Abx (Amikacin IV, clofazamine PO, clarithromycin PO)	Yes	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	0	0	1.76	SAGCFN_22_01747	23.2	TCCGGAGA	CCTATCCT	383	6.7
698917_20180128_S	698917_20180128_S		698917_20180128_S	698917	132	IP	WCH	Adol Room 1	14	3	Paediatric	F	S	71.0	11.0	3.8	102.0	16.0	0.156862745	1.44	Candida albicans	0.0	0.0	1; 4; 6		62.0	0.56		0.0	106.0	105.0	106	0.990566038	1.0	1.0	No	Yes	F508	C743+415,C1584+2987	Admission for NTM eradication - 3/12 IV abx; Needle came off during RA scan; RA scan repeated	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-14	Yes	P. aeurignosa x 2 (MDR - R to amikacin, cefepime, ciprofloxacin, gentamicin, meropenem, piperacillin/tazobactam, S to ceftazidime, tobramycin; mucoid - R to amikacin, cefepime, gentamicin, S - to all others	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2/52 of NTM Abx (Amikacin, clofazamine, clarithromycin)	Yes	1	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	0	0	0.337	SAGCFN_22_01793	21.0	TAATGCGC	TATAGCCT	495	2.2
698917_20180329_S			698917_20180329_S	698917	192	OP	WCH	Day Surgery 19	14	3	Paediatric	F	S	79.0	12.0	3.6	120.0	18.0	0.15	1.52	Candida albicans	0.0	0.0	1; 4; 6						97.0	98.0	106	0.924528302	2.0	1.0	No	Yes	F508	C743+415,C1584+2987	Completed NTM IV eradication; now on oral	No	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-06-14	Yes	P. aeurignosa x 2 (MDR - R to amikacin, cefepime, ciprofloxacin, gentamicin, meropenem, piperacillin/tazobactam, S to ceftazidime, tobramycin; mucoid - R to amikacin, cefepime, gentamicin, S - to all others	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (2/7 of PO azithromycin, PO bactrim, Inh amikacin, PO clofazamine, preceded by 3/12 of IV amikicain, imipenem, PO bactrim/clofazamine)	Yes	1	1	1	0	1	1	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	1	0	0	6	6	0	0	0.0554	SAGCFN_22_01847	5.6	GAACCGCATT	AGGCATAATG	345	2.6
720054_20171120_S			720054_20171120_S	720054	63	OP	WCH	OPD 31a	17	3	Paediatric	F	S	26.0	4.0	2.9	49.0	8.0	0.163265306	2.9	MAC (smear negative); oral flora	1.0	0.0	1; 5; 8						96.0	94.0	99	0.949494949	2.0	1.0	Impaired	Yes	F508	c.2051_2052delinsG		No	0	0	0	1	0	0	0	0	0	1	0	0	0	0	1	0	0	1	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-02-05	No (over 12 months)	Tested positive for M. avium complex, C. albicans	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (PO augmentin for 4 weeks)	Yes	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.163	SAGCFN_22_01820	40.8	TCTCGCGC	GGCTCTGA	459	1.7
720054_20170925_S			720054_20170925_S	720054	7	OP	WCH	Level 6 DK	17	3	Paediatric	F	S	61.0	9.0	3.3	101.0	15.0	0.148514851	1.66	S. aureus; H. influenzae; MAC (smear negative)	1.0	0.0	1; 5; 8						93.0	92.0	99	0.929292929	2.0	1.0	Impaired	Yes	F508	c.2051_2052delinsG		No	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	1	1	negative	0	0	0	0	0	0	0	1	0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-02-05	No (over 12 months)	Tested positive for M. avium complex, C. albicans	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.238	SAGCFN_22_01808	20.4	CGGCTATG	GTACTGAC	553	4.2
763742_20180129_S	763742_20180129_S		763742_20180129_S	763742	133	OP	WCH	OPD 34	11	3	Paediatric	F	S	17.0	4.0	3.9	24.0	6.0	0.25	1.41	Oral Flora	0.0	0.0	3; 4; 5; 8		5.0	0.0		0.0	66.0	71.0	78	0.91025641	2.0	1.0	Yes	Yes	F508	F508	Returned following Steno eradication (x2 week admission) several months prior	Yes	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	1.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	2021-01-22	No	Tested positive for S. maltophilia, A. fumigatus, MSSA, C. albicans over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No (Levofloxacin ceased 3/52 ago, ?duration)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.335	SAGCFN_22_01795	23.8	TAATGCGC	CCTATCCT	500	4.0
763742_20170925_S			763742_20170925_S	763742	7	OP	WCH	OPD 5	11	3	Paediatric	F	S	30.0	5.0	3.5	47.0	8.0	0.170212766	1.57	Candida albicans; unspecified NTM (smear negative)	1.0	0.0	8		3.0	0.0		0.0	67.0	73.0	78	0.935897436	2.0	1.0	Yes	Yes	F508	F508	Has low PFTs then BAL couple of weeks later, steno + and admitted	Yes	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	2021-01-22	No	Tested positive for S. maltophilia, A. fumigatus, MSSA, C. albicans over next 12 months	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	1.0	1.0	0.0	0.0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	No	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	SAGCFN_22_01860	0.736	TATCCGCGTC	ACGATGCAAC	549	0.5
770560_20190109_S			770560_20190109_S	770560	478	IP	WCH	Adolescent 4	12	3	Paediatric	F	S								Oral flora; Candida albicans	0.0	0.0	1; 3; 4						95.0	93.0	100	0.93	2.0	1.0	No	Yes	F508	F508	3/12 IV antibiotic admission for NTM	No	0	0	0	1	0	0	0	1	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, M. abscessus, Stenotrophomonas maltophilia over next 12 months	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV amikacin/cefoxitin, PO clofazamine/azithromycin for 3 weeks)	Yes	1	0	1	0	1	0	0	1	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	4	0	0	0.071	SAGCFN_22_01842	12.0	CTTGCTATTC	CGTGACTCTA	395	4.2
770560_20181218_S			770560_20181218_S	770560	456	IP	WCH	Adolescent 4	12	3	Paediatric	F	S								?no sputum			2; 4	Previous P. aeruginosa (non-mucoid)	76.0	0.0	60.0	0.0	97.0	91.0	100	0.91	2.0	1.0	No	Yes	F508	F508	3/12 IV antibiotic admission for NTM	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, M. abscessus, Stenotrophomonas maltophilia over next 12 months	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0			0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV amikacin, PO azithromycin for 7/7)	Yes	1	0	1	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3	0	0	0.161	SAGCFN_22_01821	14.9	TCTCGCGC	AGGCGAAG	630	3.2
1162967_20180116_S			1162967_20180116_S	1162967	120	OP	RAH	Chest Clinic 6	37	6	Adult	F	S	4.0	1.0	3.4	6.0	2.0	0.333333333	1.61	P. aeruginosa (mucoid and non-mucoid); M. terrae (intermediate grower); Aspergillus nidulans	1.0	1.0	2	Previous mucoid and non-mucoid P. aeruginosa					35.0	32.0	36	0.888888889	3.0	1.0	Yes	Yes	F508	F508	Listed for lung transplant		1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	negative	0	0	0	0	0	0	0	0	0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-01-16	Yes	Mucoid P. aeruginosa - resistant to everything except for tobramycin ; Tested positive for M. terrae complex, C. albicans over the next 12 months	1.0	1.0	1.0		1.0		1.0							0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	1/12 of oral ciprofloxacin	Yes	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.102	SAGCFN_22_01835	10.7	CGACCTTAAT	ACCTAAGAGC	357	2.8
698564_20181205_S			698564_20181205_S	698564	443	IP	WCH	Adolescent 3	15	3	Paediatric	F	S								S. maltophilia; P. aeruginosa (?aeruginosa); Unclassified rapid NTM (smear negative)	1.0	1.0	1; 2; 3		1707.0	61.5	84.0	1.0	73.0	59.0	69	0.855072464	3.0	1.0	No	Yes	F508	F508	Had cultured PA +ve in previous 12 months	Yes	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0	negative	0	0	0	0	0	0	0	0	0	0.0	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2018-12-05	Yes	S. maltophilia; P. aeruginosa (?aeruginosa); Unclassified rapid NTM (smear negative)	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	1.0				0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tobramycin/tazocin for 10/7, about to commence IV methylprednisolone)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	2	2	0	0	0.059	SAGCFN_22_01846	4.0	TCCAACTGAA	CCTACGGACA	856	2.6
670829_20171001_S			670829_20171001_S	670829	13	IP	WCH	Adolescent 6	15	3	Paediatric	F	S	1.0	1.0	3.1	2.0	2.0	1.0	1.77	A. fumigatus; A. flavus; M. abscessus (positive smear)	1.0	0.0	1; 4; 6	Previous A. flavus growth; NTM = M. abscessus; Cupriavidus gilardii					96.0	99.0	125	0.792	3.0	2.0	No	Yes	F508	F508	3/12 IV NTM admission (complicated by allergy to cefoxitin)	No	0	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	positive	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2019-01-11	No (over 12 months)	Tested positive for A. fumigatus, A. flavus, M. abscessus over next 12 months	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0				0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV amikacin for 3 days)	Yes	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.28	SAGCFN_22_01803	41.8	CGGCTATG	CCTATCCT	375	2.2
717449_20180606_S			717449_20180606_S	717449	261	IP	WCH	MSSW 16	14	3	Paediatric	F	S	26.0	11.0	4.6	31.0	13.0	0.419354839	1.19	Oral flora; M. abscessus	1.0	0.0	4		190.0	7.46	14.0	0.0	69.0	64.0	79	0.810126582	3.0	1.0	No	Yes	F508	621t1c>t	2/52 admission for acute on chronic bronchitis	No	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	positive	0	0	0	0	0	0	0	0	0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No (over 12 months)	Tested positive for M. abscessus (bolletii), M. abscessus (abscessus), C. albicans, A. fumigatus over the next 12 months					1.0		1.0		1.0					0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (PO azithromycin x 2/7, about to commence full NTM treatment; finished PO flucloxacillin 3/52 ago)	Yes	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.124	SAGCFN_22_01830	25.6	AGCGATAG	TAATCTTA	629	1.5
753522_20180606_S	753522_20180606_S		753522_20180606_S	753522	261	IP	WCH	Adol Rm2	12	3	Paediatric	M	S	38.0	16.0	4.8	43.0	18.0	0.418604651	1.14	Oral flora; C. albicans; M. abscessus	1.0	0.0	1; 4		257.0	2.07	11.0	0.0	84.0	72.0	87	0.827586207	3.0	1.0	No	Yes	F508	F508	2/52 admission for acute on chronic bronchitis and sudden PFT decline	No	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0	positive	0	0	0	0	0	0	0	0	0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, Sarocladium glaucum, M. abscessus, Stenotrophomonas maltophilia over next 12 months	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	Yes (IV tazocin x 2 doses, about to commence IV tobramycin)	Yes	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1	0	0	0.423	SAGCFN_22_01791	20.0	CTGAAGCT	CAGGACGT	590	4.3
770560_20181211_S			770560_20181211_S	770560	449	IP	WCH	Adolescent 4	12	3	Paediatric	F	S								S. aureus; S. maltophilia; Acremonium species; M. abscessus (smear positive)	1.0	0.0	2; 4	Previous P. aeruginosa (non-mucoid)					99.0	97.0	100	0.97	1.0	1.0	No	Yes	F508	F508	3/12 IV antibiotic admission for NTM	No	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	0	0	positive	0	0	0	0	0	1	0	0	0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		No	Tested positive for C. albicans, M. abscessus, Stenotrophomonas maltophilia over next 12 months	0.0	0.0	0.0	0.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0			0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	No (About to commence IV imipenem/amikacin, PO azithromycin/clofazamine)	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0	SAGCFN_22_01857	14.9	TTACTTCGTG	ATCCGATCTT	362	2.4
